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Investigations of Pharmacokinetic Challenges in Premature Infants
Abstract
Premature infants (gestational age less than 37 weeks) are considered a vulnerable patient population
due to their immaturity at birth. Currently, off-label prescribing is common in younger pediatric
populations, especially in premature neonates and infants, which is a primary group receiving intensive
care. Unique pharmacokinetic (PK) challenges—such as limited blood volume and frequency of blood
sample collections, rapid growth and continuous developmental changes, complexity of pediatric studies
as well as scientific, practical, and ethical concerns— lead to the current lack of PK information and
empirical dosing in premature neonates and infants. In this research, several approaches were
investigated to overcome these PK challenges. We first developed and validated an accurate and
sensitive LC-MS/MS method that can simultaneously quantitate multiple drugs frequently used in
pediatric pharmacotherapy using a small volume of plasma. Additionally, a modeling and simulation
(M&S) approach was explored in the theophylline population pharmacokinetic (PopPK) study in order to
get an appropriate study design with the optimized sample size. Finally, PopPK of caffeine was
investigated in premature infants using clinical data. Optimized dosing regimens were developed based
on the PopPK model and dose-finding simulation study.
Due to the limitation in sample volume, an assay that can simultaneously determine multiple drugs allows
for gaining maximal information from PK studies while minimizing the burden of blood collection in
pediatric patients. Acetaminophen, caffeine, phenytoin, ranitidine, and theophylline are widely used in the
pharmacotherapy of premature and term neonates, but only limited information is currently available on
the PK of these medications in premature neonates. An accurate, sensitive and reliable LC-MS/MS assay
was developed and validated using 50 µL human plasma specimens to simultaneously quantitate these
five drugs with the mean accuracy ranging from 87.5 to 115.0%. The intra-day and inter-day precisions
ranges from 2.8% to 11.8%, 4.5% to 13.5% respectively. This assay quantifies a range of 12.2 to 25,000
ng/mL for acetaminophen, phenytoin, and ranitidine, a range of 24.4 to 25,000 ng/mL for theophylline, and
a range of 48.8 to 25,000 ng/mL for caffeine. These ranges cover each drug’s therapeutically used
concentrations in the neonatal group. No significant interference effects from hemolysis, lipemia and
hyperbilirubinemia were noted when these factors existed separately or were combined. Additionally, no
significant matrix effect was observed for the developed bioanalytical assay.
We then evaluated the impact of sample size on the robustness of PopPK parameter estimates in
observational studies in premature neonates using a simulation approach with theophylline as the model
drug. Simulated datasets for each sample size (9–200 subjects per study) with a mixed and unbalanced
sampling design were first generated with the incorporation of changes in birth weight, body weight, and
postnatal age (PNA) in premature neonates. The median PopPK parameters for theophylline estimated
from the simulated datasets were generally in close agreement with those of the originating model across
all tested sample sizes. While the accuracy, precision and power to parameter estimation benefit from
increases in the number of subjects included in the study, an observational study designs with < 20
premature neonates and unbalanced sampling are inadequate to allow for the precise estimation of
theophylline PopPK parameters. Furthermore, the results indicate that the impact of sample size on the
power of the study was deeply influenced by the parameter of interest and the selected precision level. To
detect all three covariate effects studied in this research with a power > 0.8, a sample size of 20, 40 and
60 subjects is required to reach the significant level of P = 0.05, P = 0.01 and P = 0.001, respectively. The
application of PopPK modeling and simulation provides a useful approach to estimate the number of
subjects needed to confidently detect the potential covariate effects on PK parameters under a specific
sampling strategy—randomized and unbalanced blood sampling schedules, which is consistent with
actual pediatric clinical settings.

Apnea of prematurity (AOP) is one of the major concerns in premature neonates. Caffeine is currently the
first-line pharmacotherapy frequently used for the treatment of AOP. A PopPK model of caffeine was
developed in premature neonates, and potential sources of variability of PK behavior for caffeine were
also identified. A one-compartment model was chosen to describe the PK characteristics of caffeine in
premature infants, covering a gestational range of 23 to 31 weeks with an age of up to 116 days. Body
weight (WT), postconceptional age (PCA) and a low gestational age (GA) of < 25 weeks were found to be
important predictors explaining the between-subject variability of caffeine PK in premature infants
receiving caffeine treatment. The typical patient in the studied premature neonate population, i.e., a
patient with WT of 1.5 kg, PCA of 32 weeks and with a GA > 25 weeks, is estimated to have a CL of 0.0164
L/hr and a V of 0.94 L. We also investigated the application of this PK knowledge to facilitate the
development of optimal dosing regimens further through simulation, particularly to correlate steady state
concentrations with response at the different dosing regimens for various age/body size groups using
trial simulation. A dosing interval of 24 hours is shown to be successful with respect to the proposed
target concentrations in all simulated groups. With the proposed dosing regimens, the predetermined
target was attained and the simulated median trough plasma concentrations were between 8 and 20 mg/
L throughout the treatment period. The dose-finding simulations based on the developed PopPK model
may provide more benefit while allowing the clinicians to compare various dosing regimens and bridge
the plasma caffeine levels with responses at different PCAs and different WTs.
In summary, different approaches were investigated in this study to overcome the unique PK challenges in
the premature neonates and infants. A full model-based simulation approach was developed to determine
an optimal sample size for PopPK study in premature neonates with the consideration of changes in birth
weight, body weight, and PNA. In addition, a PopPK model was developed for caffeine in premature
infants and optimal dosing regimens were proposed to reach the therapeutic target concentrations rapidly
based on the PopPK model. Together with the developed LC-MS/MS assay, which is highly sensitive,
accurate and reliable, population-based modeling and simulation are highly useful in supporting clinical
PK studies in premature neonates and infants.
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ABSTRACT
Premature infants (gestational age less than 37 weeks) are considered a vulnerable
patient population due to their immaturity at birth. Currently, off-label prescribing is
common in younger pediatric populations, especially in premature neonates and infants,
which is a primary group receiving intensive care. Unique pharmacokinetic (PK)
challenges—such as limited blood volume and frequency of blood sample collections,
rapid growth and continuous developmental changes, complexity of pediatric studies as
well as scientific, practical, and ethical concerns—lead to the current lack of PK
information and empirical dosing in premature neonates and infants. In this research,
several approaches were investigated to overcome these PK challenges. We first
developed and validated an accurate and sensitive LC-MS/MS method that can
simultaneously quantitate multiple drugs frequently used in pediatric pharmacotherapy
using a small volume of plasma. Additionally, a modeling and simulation (M&S)
approach was explored in the theophylline population pharmacokinetic (PopPK) study in
order to get an appropriate study design with the optimized sample size. Finally, PopPK
of caffeine was investigated in premature infants using clinical data. Optimized dosing
regimens were developed based on the PopPK model and dose-finding simulation study.
Due to the limitation in sample volume, an assay that can simultaneously
determine multiple drugs allows for gaining maximal information from PK studies while
minimizing the burden of blood collection in pediatric patients. Acetaminophen, caffeine,
phenytoin, ranitidine, and theophylline are widely used in the pharmacotherapy of
premature and term neonates, but only limited information is currently available on the
PK of these medications in premature neonates. An accurate, sensitive and reliable
LC-MS/MS assay was developed and validated using 50 µL human plasma specimens to
simultaneously quantitate these five drugs with the mean accuracy ranging from 87.5 to
115.0%. The intra-day and inter-day precisions ranges from 2.8% to 11.8%, 4.5% to
13.5% respectively. This assay quantifies a range of 12.2 to 25,000 ng/mL for
acetaminophen, phenytoin, and ranitidine, a range of 24.4 to 25,000 ng/mL for
theophylline, and a range of 48.8 to 25,000 ng/mL for caffeine. These ranges cover each
drug’s therapeutically used concentrations in the neonatal group. No significant
interference effects from hemolysis, lipemia and hyperbilirubinemia were noted when
these factors existed separately or were combined. Additionally, no significant matrix
effect was observed for the developed bioanalytical assay.
We then evaluated the impact of sample size on the robustness of PopPK
parameter estimates in observational studies in premature neonates using a simulation
approach with theophylline as the model drug. Simulated datasets for each sample size
(9-200 subjects per study) with a mixed and unbalanced sampling design were first
generated with the incorporation of changes in birth weight, body weight, and postnatal
age (PNA) in premature neonates. The median PopPK parameters for theophylline
estimated from the simulated datasets were generally in close agreement with those of the
originating model across all tested sample sizes. While the accuracy, precision and power
to parameter estimation benefit from increases in the number of subjects included in the
vi

study, our simulation showed observational study designs with < 20 premature neonates
and unbalanced sampling are inadequate to allow for the precise estimation of
theophylline PopPK parameters. Furthermore, the results indicate that the impact of
sample size on the power of the study was deeply influenced by the parameter of interest
and the selected precision level. To detect all three covariate effects studied in this
research with a power > 0.8, a sample size of 20, 40 and 60 subjects is required to reach
the significance level of P = 0.05, P = 0.01 and P = 0.001, respectively. The application
of PopPK modeling and simulation provides a useful approach to estimate the number of
subjects needed to confidently detect the potential covariate effects on PK parameters
under a specific sampling strategy—randomized and unbalanced blood sampling
schedules, which is consistent with the actual pediatric clinical settings.
Apnea of prematurity (AOP) is one of the major concerns in premature neonates.
Caffeine is currently the first-line pharmacotherapy frequently used for the treatment of
AOP. A PopPK model of caffeine was developed in AOP patients, and the potential
sources of variability of PK behavior for caffeine were also identified. A onecompartment model was chosen to describe the PK characteristics of caffeine in
premature infants, covering a gestational range of 23 to 31 weeks with an age of up to
116 days. Body weight (WT), postconceptional age (PCA) and a low gestational age
(GA) of < 25 weeks were found to be important predictors explaining the betweensubject variability of caffeine PK in premature infants. The typical patient in the studied
premature neonate population, i.e., a patient with WT of 1.5 kg, PCA of 32 weeks and
with a GA > 25 weeks, is estimated to have a clearance of 0.0164 L/hr and a volume of
distribution of 0.94 L. We further investigated the application of this PK knowledge to
facilitate the development of optimal dosing regimens through simulations, particularly to
correlate steady state concentrations with response at the different dosing regimens for
various age/body size groups using trial simulation. A dosing interval of 24 hours is
shown to be successful with respect to the proposed target concentrations in all simulated
groups. With the proposed dosing regimens, the predetermined target was attained and
the simulated median trough plasma concentrations were between 8 and 20 mg/L
throughout the treatment period. The age-specific dose-finding simulations based on the
developed PopPK model may provide more therapeutic benefit while allowing the
clinicians to compare various dosing regimens and bridge the plasma caffeine levels with
responses at different PCAs and different WTs.
In summary, different approaches were investigated in this study to overcome the
unique PK challenges in premature neonates and infants. A full model-based simulation
approach was developed to determine an optimal sample size for PopPK study in
premature neonates with the consideration of changes in birth weight, body weight, and
PNA. In addition, a PopPK model was developed for caffeine in premature infants and
optimal dosing regimens were proposed to reach the therapeutic target rapidly based on
the PopPK model. Together with the developed LC-MS/MS assay, which is sensitive,
accurate and reliable, population-based modeling and simulation are highly useful in
supporting clinical PK studies in premature neonates and infants.
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CHAPTER 1.

INTRODUCTION

Pediatric Populations and Off-label Medications
Federal legislation and the U.S. Food and Drug Administration (FDA) regulations
require that drugs be tested for safety and efficacy in the intended patient population
before they are approved for marketing. Prescribing of drugs without appropriate testing
and FDA approval for a specific age or diagnosis is thus considered “off-label” or
unlicensed use. While more than 200 new drugs have been approved by the FDA over the
last decade, the development and evaluation of new medicines in pediatric populations
remains limited and particularly scarce in premature and term neonates [1]. The paucity
of evidence-based medicines for children is still an extensive, long-standing problem
across almost all therapeutic categories including infection, respiratory diseases, central
nervous system disorders and gastrointestinal diseases, as well as pain control
(Figure 1-1) [2-9]. For example, it has been reported that up to 62% of pediatric
outpatient visits involve prescribing off-label or unlicensed medications [3]. Among this
62% percent, off-label prescribing was observed in 96% of the pediatric patients with
cardiovascular and renal diseases, over 80% of those requiring pain management
therapies or diagnosed with gastrointestinal diseases and 67% of patients with pulmonary
or dermatologic diseases. Similarly, another study reported that 70% of the medications
in pediatric intensive care and 90% of the medications in neonatal intensive care were
given in an off-label manner [10].
Pediatric populations are defined as neonates (from birth to 1 month), infants
(from 1 month to 2 years), children (from 2 to 12 years), and adolescents (from 12 to
< 16 years) in clinical studies. based on the United States Food and Drug Administration
(FDA) guidance [11]. Within pediatric populations, premature neonates whose
gestational age (GA) is less than 37 weeks are considered the youngest and most
vulnerable patient population to adverse drug reactions due to their immaturity at birth.
Premature neonates in the intensive care unit have the highest use of off-label
medications of any hospitalized patient population. Generally, off-label or empirical drug
dosing is not considered unethical or illegal and may in fact be beneficial to the patients.
However, given the fact that off-label dosing is usually carried out based upon clinicians’
experiences, limited published literature and extrapolations from adult dosing regimens
[12], it has been associated with adverse events and raises concerns regarding proper dose
selection as well as safety and efficacy [3, 13, 14]. For example, immature liver enzyme
activity and low renal excretion function were observed in premature and term neonates
compared to adults and older children [15], and these findings may indicate decreased
clearance and therefore larger exposure to drugs. A classic example is the “grey baby
syndrome” with the administration of chloramphenicol in neonates [16]. The age-related
incidence of gray baby syndrome was most found in newborns less than 9 days old [16,
17]. The reduced capacity of the liver and kidney to detoxify and eliminate
chloramphenicol explains the development of toxic effects in neonates, especially in
premature neonates given body-weight scaled chloramphenicol doses [18]. Another
possible reason is that children may show development-associated toxicity that adults do
1

Figure 1-1.
population

Percentage of off-label drug use in major drug category in pediatric

Figure shows most often prescribed off-label drug categories in pediatrics.
Source: Figure based on data from Bazzano, A.T., et al., Off-label prescribing to children
in the United States outpatient setting. Acad Pediatr, 2009. 9(2): p. 81-8.
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not experience. For example, tetracycline-induced discolorations of teeth only affect
developing enamel during the period of calcification [19]. Therefore tetracycline is today
no longer prescribed for young children and pregnant women. These two examples
illustrate pharmacokinetic (PK) and pharmacodynamic (PD) differences between adults
and young children resulting in very disparate responses to drug therapy. However, the
differences in how PK and/ or PD interact in a fast growing child have not been
thoroughly investigated. In such cases, linear predictions from adult doses (e.g., dose
extrapolation on the basis of linear scaling per body surface area [BSA] or per body
weight [WT]) are not always suitable solutions.
The American Academy of Pediatrics Committee on Drugs has stated: “There is
a moral imperative to formally study drugs in children so that they can enjoy equal access
to existing as well as new therapeutic agents” [20]. To correct the situation of off-label
dosing, a series of laws and regulations have been enacted regarding the integrity of the
research and development of therapies for pediatric patients. Recent legislative incentives
and regulations for pediatric drug development are summarized in Table 1-1.
The Pediatric Labeling Rule issued by the FDA in 1994 encourages sponsors to
review existing data and provide the appropriate labeling information for pediatric use if
the course of the disease and the expected drug responses are similar between adult and
pediatric populations. However, only a small increase in the number of applications with
supplemental pediatric labeling information was noticed following the Pediatric Labeling
Rule [21]. The FDA Modernization Act (FDAMA) issued in 1997 included financial
incentives for pharmaceutical companies to conduct pediatric studies. This act offered an
additional 6 months of marketing exclusivity for a drug tested in pediatric studies and
also led to the development of an annual Pediatric Priority List by the FDA, which
consists of approved drugs that need new pediatric use information. In 1998, the FDA
published the Pediatric Rule, which required that any new drug application contain the
data from pediatric testing unless this drug was not going to be used in a substantial
number of pediatric patients. Under the Pediatric Rule, the FDA also required drug
companies to perform pediatric studies for a marketed drug when the drug was used or
intended to be used in pediatric patients but lacked labeling information where the drug
might cause significant risks. The change of an active ingredient, formulation, dosage or
route of administration of a drug may trigger this rule [21]. However, the Pediatric Rule
Table 1-1.
Summary of regulatory incentives and regulations for drug
development in pediatric populations
Year
1994
1997
1998
2002
2003
2007

Regulatory incentives or regulations
Pediatric Labeling Rule
FDA Modernization Act (FDAMA)
Pediatric Rule
Best Pharmaceuticals for Children Act (BPCA)
Pediatric Research Equity Act (PREA)
FDA Amendments Act
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was overturned by a federal court in 2002. More recently, the Best Pharmaceuticals for
Children Act (BPCA) took effect in 2002 and aimed to improve pediatric drug
development as well as to encourage testing of new drugs and off-patent drugs for use in
pediatric populations. The Pediatric Research Equity Act (PREA) was signed into law in
2003; it authorizes the FDA to require clinical studies in pediatric populations for new
drugs and biological products targeting pediatric patients. To reauthorize the BPCA and
PREA, the FDA Amendments Act was enacted in 2007; it extended the 6-month
additional market exclusivity for patented drugs when clinical studies are being
conducted in pediatric populations.
Role of Pharmacokinetics and Pharmacodynamics in Pediatric Optimal Dosing
In the previous section, a couple of examples explicating different drug responses
derived from large variability in pharmacokinetics and pharmacodynamics between
adults and children were mentioned. These differences also exist within the gestational
age variance of premature infants. Premature infants are not a homogenous group; their
maturational process after birth may follow various patterns. Developmental changes in
body size and function are rapid and continuous. A variety of changes in physiological
and biochemical processes resulting in age-dependent differences in drug disposition
(i.e., absorption, distribution, metabolism and excretion) and drug response also exist in
these infants.
PKPD and optimal dose selection
Pharmacokinetics describes the effect of the body on drugs, including the process
of absorption, distribution, metabolism and excretion (ADME) of a drug over a certain
period of time. Pharmacodynamics describes the relationship between drug
concentrations and the magnitude of drug effect at the assumed site of drug action. In
other words, PK and PD may be simply defined as ‘what the body does to the drug’
and ‘what the drug does to the body’ [22]. The PK and PD characteristics may explain
the clinical responses of certain dosing regimens of a drug independently or their
combined effect—i.e., dose–exposure–response relationship can play an important role in
deciding the optimal dosing regimen with maximal efficacy and minimum undesirable
drug effects. The exposure-response relationship for pediatric clinical pharmacology may
not be the same as for adults. The understanding of the PK and/or PD relationship can
provide a rational and scientifically based framework for the determination of the optimal
dosing regimen in pediatric pharmacotherapy. When a similar concentration-response
relationship can be assumed between pediatrics and adults and when PK is the major
factor contributing to differences in drug responses, optimal dose selection can be
determined based on the PK characteristics of the drug. One example is topiramate,
which is a recently approved drug for the monotherapy of seizures in pediatric patients
2-10 years old [23]. Topiramate has been previously approved as monotherapy in patients
> 10 years of age or as adjunctive therapy for pediatric patients 2-10 years of age. In this
study, a similar exposure-response relationship was proven between pediatric patients
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and adults through PK/PD modeling and simulation. Therefore, the dosing regimen for
pediatric patients 2-10 years old was derived based on PopPK modeling and simulation
without additional clinical trials. Meanwhile, dose optimization also may be determined
by the drug’s PK and PD properties simultaneously when both PK and PD characteristics
are changing. For example, dosing recommendations for sotalol have been derived when
both PK and PD data were considered [24]. In this study, different concentration-QT
prolongation relationships were revealed through population PK/PD analysis between
neonates and older patient groups. Based on the findings, both solatol’s systemic
exposures and PD responses were included in the development of sotalol dosage
recommendations in different pediatric age groups to achieve maximum efficacy and
minimum safety concerns.
Age-dependent changes in PKPD
Absorption
Absorption of oral drugs can be affected by gastric acidity, gastric motility and
emptying time, as well as the length of the gastrointestinal tract. Gastric acidity, which is
decreased in neonates and infants, can enhance the absorption of acid labile drugs, such
as benzylpenicillin and ampicillin, and decrease the absorption of acidic drugs, such as
phenobarbital and phenytoin [25]. Gastric pH then changes gradually during maturation
and slowly reaches adult levels approximately 2 years after birth. In addition, gastric
emptying is much slower in premature infants compared to term infants and older
children [26]. Thus bioavailability of oral drugs in premature infants can be very different
from that in term infants and older children.
Distribution
Drug distribution is also different in neonates and infants and is greatly influenced
by total body water and protein binding. Total body water is approximately 85% of the
body weight in premature neonates and 70-75% in term neonates compared with 50-55%
in adults. As a result, a larger dose (per body weight) is required for polar compounds to
achieve therapeutic concentrations in neonates [25]. Additionally, volume of distribution
can be affected by protein binding. Due to the lower levels, protein binding of drugs is
generally reduced in neonates, especially premature neonates, as compared to that in
older children and adults. Reduced protein binding also leads to a higher fraction of
unbound plasma drug concentrations, which results in a larger volume of distribution for
medications used in newborns. For example, it has been reported that with administration
of theophylline a lower protein binding and a larger volume of distribution were observed
in preterm neonates than in older children and adults [27].
Metabolism
Drug metabolism defines the biotransformation of endogenous and exogenous
compounds in the body. It may occur in the liver, kidneys, intestines, lungs and blood
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cells, but hepatic metabolism is the primary pathway for most drugs’ metabolism.
Hepatic metabolism is usually catalyzed in the liver by the cytochrome P450 (CYP)
enzymes (Phase I reactions), and/or the Phase II enzymes, such as uridine diphosphate
glucuronosyl transferase, sulfotransferase, methyltransferase, glutathione S-transferase
and N-acetyltransferases. Metabolism generally enhances drug excretion by transforming
xenobiotics and drugs into a more water-soluble form [28]. These metabolic pathways are
generally underdeveloped at birth and change dramatically from birth to adulthood. The
rates of maturation for metabolizing enzymes are much slower in premature neonates
than in term neonates [25].
Although liver expression of major Phase I enzymes, such as the CYP1A,
CYP2C, CYP2D, CYP2E and CYP3A subfamilies, are generally very low in neonates
and reach adult levels within 2 years after birth, the age-dependent developmental
trajectory might be different between different type of enzymes. For example, CYP3A4 is
the most abundant isozyme in the CYP family in the adult liver and accounts for the
metabolism of more than 30% of all drugs, while CYP3A7 is the predominant enzyme of
the CYP3A family in the fetal liver [29, 30]. CYP3A7 activity remains maximal within
one week after birth but then decreases to a very low level. Concurrently, CYP3A4
enzyme activity increases after birth, reaching approximately 30-40% of adult levels by
one month of age, and actually exceeds adult levels by two years of age [29, 31]. The
CYP2C enzymes are an important subfamily of CYPs and are involved in the metabolism
of ~20% of clinically used drugs in adults [32]. Of them, CYP2C9 and CYP2C19 are
two predominant isozymes. CYP2C9 protein and activity levels are comparable to adult
values at birth, while CYP2C19 enzyme activity is only 12 to 15% of adult values at birth
and reaches adult levels after 10 years of age [33]. Very low levels of CYP2D6 protein
can be detected in the fetal liver and are associated with the O-demethylation activity of
dextromethorphan [34, 35]. CYP2D6 activity increases rapidly after birth and reaches
approximately 30% of adult levels by the first month of life [34]. Adult levels of
CYP2D6 enzyme activity may be reached by one year of age [36]. CYP1A2 enzyme
activity is negligible at birth and remains very low until one to three months after birth.
Its activity increases to approximately 50% of adult values by one year of age [37].
Phase II enzymes also contribute significantly to the elimination of many
clinically used drugs. Though the information for the ontogeny of Phase II metabolizing
enzymes is still limited, current literature indicates that developmental changes of many
Phase II enzymes occur throughout infancy and usually exhibit isoform-specific
maturation process [38]. Therefore, reduced ability to eliminate exogenous and
endogenous compounds also may be observed in neonates and infants because of the low
conjugation capacity of the Phase II enzymes.
As a result, drugs that are metabolized by the Phase I and Phase II enzymes may
exhibit a low systemic clearance and prolonged elimination half-life in neonates; but a
higher weight-corrected dose may also be needed during infant or children period when
metabolizing enzyme activities reach adult levels due to nonlinear scaling requirements
between children and adults. Although expression of some hepatic enzymes might appear
to be associated with birth, both postconceptional and postnatal development can affect
hepatic drug clearance in neonates. Postconceptional age is considered a more
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physiologically appropriate factor to explain maturation-dependent drug metabolism, as it
explains the maturation and developmental process of drug metabolic pathways both
prior to and after birth [39].
Xenobiotics and their metabolites can be excreted from cells by Phase III
transporters, most of which belong to the ATP-binding cassette family (ABC) or the
solute carrier transporter family. Phase III transporters are present in the cell membrane
of many tissues, such as liver, intestine, kidney and brain, and can provide a barrier
against xenobiotic entry or move various endogenous and exogenous compounds in and
out of cells. For example, Phase III transporters are involved in the excretion of drugs and
their metabolites into the bile for hepatic elimination and are essential components
contributing to the overall hepatic clearance.
The ABC transporters are a superfamily of large membrane proteins that can
actively transport a variety of compounds through membranes in an ATP-dependant
manner [40], and human ABC transporters can be divided into seven subfamilies. Among
these subfamilies, multidrug resistance P-glycoprotein (P-gp, coded by the
MDR1/ABCB1 gene) and multidrug resistance protein 2 (MRP2, coded by ABCC2 gene)
appear to be the most relevant transporters for the hepatobiliary elimination of
xenobiotics in humans. P-gp exists in many major organs including liver, kidney, small
intestine, and blood brain barrier and plays an important role in the disposition of a
variety of hydrophobic and cationic drugs. MRP2 is highly expressed in the liver,
intestine, and kidney and transports a range of drugs conjugated to glutathione, sulfate, or
glucuronate into bile [40].
Although Phase III transporters may significantly influence drug absorption and
elimination, the developmental changes of drug transporters remains largely unknown.
For example, loperamide (a P-gp substrate)-induced respiratory depression due to central
nervous toxicity has been reported in infants despite its apparent safety in adults [41, 42].
However, it is unclear whether or not this toxicity is caused by the lower expression of
P-gp at the blood brain barrier in infants. Additionally, one recent study has reported that
P-gp is expressed in a developmental and cell-specific manner in the human central
nervous system [43]. Thus, it is possible that the expression pattern of P-gp at the blood
brain barrier might affect the uptake or excretion of drugs in the central nervous system
in neonates. Similarly, potential MRP2-related drug toxicity has been reported in
pediatric populations [44-47]. Ceftriaxone, an antibiotic often used to treat lower
respiratory infections or acute otitis media in the pediatric population, is partially
eliminated unchanged into the bile through the MRP2 transporter. An increased risk of
cholestasis has been reported in children receiving the administration of ceftriaxone,
which may be caused by the lower expression of MRP2 in pediatric patients, thus leading
to an accumulation of ceftriaxone in the hepatocytes. However, further investigations are
still needed to confirm the underlying mechanism of this adverse drug reaction.
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Excretion
Renal elimination mechanisms include glomerular filtration, active secretion and
tubular reabsorption. The maturation of glomerular filtration differs between term and
preterm infants and may affect the drug’s renal elimination. Glomerular filtration rates
are only approximately 30% of adult function at birth and mature during infancy with an
exponential function that asymptotically reaches adult values [39]. Adult levels are
reached within 1 year of age for a full term infant [48]. Premature infants have a much
smaller increase in glomerular filtration rate during the first 3 days after birth than term
infants [49]. Various transporters such as ABC transporters, organic anion/cation
transporters (OATs/OCTs) and the peptide co-transporter PEPT2, are involved in renal
secretion and reabsorption [50]. However, little information is known about the
maturation process of these transporters in the kidney.
Developmental changes in pharmacodynamics
Both PK and PD processes contribute to the difference in the safety and efficacy
of a drug between pediatric populations and adults. A decision tree for conducting
pediatric studies was proposed by the FDA in 2003 [51]. The FDA guidance for bridging
efficacy studies recommends the evaluation of disease progression, drug response and
concentration-response relationship between adults and pediatric populations. Although
currently there is little known regarding the developmental changes in PD responses, a
number of studies have reported age-dependant changes in the concentration-response
relationships of some drugs. For example, Tran et al. reported that the antisecretory effect
following a single oral lansoprazole administration was increased in infants younger than
6 months compared to that in older children and adults [52]. Similarly, age-related
differences in PD responses have been reported for tacrolimus [53], cyclosporine [54],
sotalol [24], rocuronium [55], and warfarin [56].
These maturation processes in premature neonates and infants have significant
impact on a drug’s dose-concentration relationship, which may lead to profound agedependent differences in PK and PD responses. Drugs, including newly developed and
established ones, must be investigated in children to determine their safety and efficacy in
corresponding age groups. However, only therapeutic studies or routine care studies are
considered ethically acceptable research in children. New research approaches have been
proposed to overcome those challenges.
Challenges of Clinical Studies in Pediatric Patients
As mentioned earlier, the prevalence of off-label medications use in neonates and
young infants is most likely due to the greater challenges in conducting clinical studies in
this population as well as inadequate knowledge of developmental pharmacology [3, 4,
57]. This situation is even worse for premature infants. Some unique challenges in
clinical studies in this population are illustrated in Figure 1-2. In the United States the
preterm birth rate has been on the rise for more than two decades, with a rate of 12.3% in
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2008 [58]. Despite advances in neonatal care, premature neonates and infants remain a
major group for morbidity and mortality in all infants. As this population expands,
researchers are gaining more and more awareness for the need for rational and scientificbased pharmacotherapy other than empirical-based dosing.
Health problems in premature infants
Compared to term infants, premature infants face much higher rates of health
issues after birth. Briefly, common problems include but are not limited to: 1. low birth
weight, 2. feeding problems, 3. severe infections, and 4. immaturity of major organs or
organ systems. For example, almost all newborn babies with body weight < 1000 g or
with gestational age < 29 weeks have breathing problems to some extent due to
underdeveloped lungs and a resulting insufficient oxygen supply. Special care is often
needed to support their lives for weeks to months. Medical and ethical concerns highly
restrict the performance of clinical research in this patient group. As a result, new drug
testing usually excludes pediatric populations from therapeutic research for the
establishment of evidence-based medicine, except for therapeutic studies or routine care
studies.
Limited sample volumes in pediatric studies
The volume and frequency of blood sample collection in infants and small
children are usually very limited. While no consensus has been reached on the
appropriate level of pediatric blood collection, various criteria have been proposed to
minimize the volume of blood withdrawn in pediatric studies. For example, the Partners
Human Research Committee (PHRC) recommended that no more than 3 mL/kg of blood
may be drawn per 8-week period for research purposes in children [59]. The European
Commission recommended that no more than 3% of the total blood volume may be
drawn for research purposes over a 4-week period in neonates and children [60].
Therefore, clinicians and researchers are urged to pay special attention on developing
sensitive assays that allow for the determination of drug concentrations by using a small
volume of blood samples.
In addition to the issues addressed above, there are numerous barriers to
conducting clinical studies in premature infants, including scientific, ethical, practical and
financial limitations. All of these challenges hinder further evaluation of new drugs and
established treatments in children. Thus, research to gain a broad understanding of
developmental changes in pharmacokinetics and pharmacodynamics in young children
needs to take advantage of appropriate research tools to develop the best dosing strategies
for young children.
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Some Research Strategies in Pediatric Studies
Quantitative assays: liquid chromatography tandem mass spectrometry
(LC-MS/MS) technique
In order to overcome some of the limitations of PK studies in young children,
innovative analytical approaches to facilitate pharmacokinetic evaluation in children are
needed. Liquid chromatography coupled with tandem mass spectrometry detection
(LC-MS/MS) has developed into a powerful, analytical approach because of its
robustness, high sensitivity, selectivity and accuracy, allowing for reliable drug and
metabolite quantification at low therapeutic levels. Given the fact that 90% of
medications used in the NICU are off-labeled, there is a great need for the study of
medication commonly used by newborn infants to ensure their safety and efficacy. The
ability to determine multiple analytes within one small volume of biological fluids
(mostly plasma) at one time is highly favorable in pharmacokinetic studies of newborns.
This feature is of great benefit because it enables researchers to gain the maximum
amount of PK information in different drugs through the quantitation of multiple drugs
from a single micro volume of plasma, thus minimizing the burden of invasive venous
punctures in infants involved in pharmacokinetic studies. A number of quantitative assays
using LC-MS/MS methodology have been previously described [61-67]. The focus on
this analytical technology allows us to rapidly establish flexible assays to quantify drugs
of interest classified by their physicochemical properties. The most commonly prescribed
medications for premature neonates in the NICU and for infants were placed on the top of
the priority list to be studied. Among them, acetaminophen, caffeine, phenytoin,
ranitidine and theophylline were included in our current study.
Population pharmacokinetics
Modeling and simulation (M&S) are methods that have been widely used in drug
development to support study design, data analysis, and study decision making. Modeling
allows for a quantitative description of pharmacokinetic and/or pharmacodynamic
properties of the investigated drugs by analyzing the observed data from preclinical and
clinical studies. It is usually expressed in a simplified manner, such as focusing only on
the important factors, to characterize a system or process [68]. Simulation refers to the
use of established pharmacokinetic and/or pharmacodynamic models to predict future
outcomes that have not been investigated experimentally. Model-based drug development
has been widely recognized as an invaluable tool in clinical research and is also
recommended by the FDA to be applied to drug development to improve knowledge
management and decision making [69].
Traditional PK and PopPK
The traditional PK approach is widely used in the early phase of drug
development. It usually involves a small group of subjects who are followed with an
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intensive pre-defined sampling scheme. Some special populations, such as the elderly,
pediatric patients or severe anemia patients, are not suitable for these study interventions
due to ethical and medical concerns. To characterize the pharmacokinetics of the studied
population in a traditional PK study, a standard two-stage (STS) approach is applied:
First each individual’s PK parameters is estimated from dense sampling, and then
population parameters are expressed as mean and standard deviation of the estimated
individuals. For the most part, mean values of the parameters have little or no bias, but
estimation of between-subject variability is biased due to the small number of studied
subjects. A rich data set will provide the most accurate information.
Application of population pharmacokinetics (PopPK) was first introduced in the
1970s by Sheiner and colleagues [70]. Today, PopPK has become a standard approach to
investigate PK data during drug development and evaluation. PopPK is defined as the
study of the sources and correlates of variability in drug concentrations among
individuals who represent the target patient population receiving the clinically relevant
doses of a drug [71]. Compared to traditional PK, it has several advantages in data
analysis. It allows for simultaneously analyzing pooled data from multiple subjects with a
relatively flexible sampling scheme. The number of samples from each subject can be
sparse, dense or a combination of sparse and dense data (mixed sampling), and sampling
times do not have to be same from all patients. This can greatly reduce the individual
burden of blood sampling as well as adapt to the patients’ convenience for blood
sampling. It allows simultaneous estimation of the typical values of PK parameters in the
targeted population and identifies the sources and magnitude of the variability as well.
Through the population analysis, variability in the PK and PD response due to predictive
factors or covariates (such as demographics, genetics, concomitant drug administration,
pathophysiological conditions, disease status, food effects, formulation, etc.) can be
considered and identified. The analysis also provides empiric Bayesian estimates of
individual parameters and parameter associated between-subject variability, which
subsequently can be used for individualized dosing strategy.
PopPK and nonlinear mixed effects model
Nonlinear mixed effects modeling is often used to perform PopPK analyses. The
typical model includes fixed effects (θ) and two levels of unexplained variability (random
effects), between-subject variability (η) and residual variability (ε). η describes the
differences between the typical population parameter θ and the individual-specific
parameter estimate. Its distribution is assumed to be normal, with mean of 0 and variance
of ω2. ε describes the difference between model predicted concentration and observed
concentration, with expected distribution of mean 0 and variance σ2 [72]. Residual error
could come from incorrect dosing, sampling record errors, assay error, within-subject
variability, or model misspecification.
The PopPK model process includes two primary components: a structural model
and a covariate model. The structural model, which most times is also referred to as the
base model, is the simplest model ready for stepwise model building. Generally, the
structural model is the model that can best describe the data without any covariate.
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However, in some special cases, it’s widely believed that a relationship between model
parameters and a predictive factor can also become part of the structural model a priori.
An example is size adjustment using the fixed-exponential allometric model a priori in
pediatric PopPK analysis [73]. The covariate model building process explores and
identifies factors that are important in explaining/reducing between-subject variability
and residual variability. In premature neonates and infants, age (gestational age, postnatal
age [PNA], postconceptional age [PCA]) and size (body weight, birth weight [BW], body
surface area, lean body weight) are two classes of significant factors correlated to
maturation process. Other examples of covariates are concomitant medication, genotype,
and biomarkers. Covariates can be added into the base model in a stepwise fashion, either
with proportional, exponential, fractional or additive relationships, depending on their
nature (categorical or continuous) and their correlation to parameters [74, 75].
Several software packages are capable of handling population-based PKPD
analysis [76], including NLME (Bell Labs, Murray Hill, New Jersey), WinNONMIX®
(Pharsight Corporation, Mountain View, California), Monolix (LIXOFT, Orsay, France),
WinBUGS (Bayesian via Markov Chain Monte Carlo [MCMC] methods, MRC
Biostatistics Unit, Cambridge, UK), SAS (SAS Institute, Cary, North Carolina),
S-ADAPT (Biomedical Simulations Resource, Los Angeles, California), and S-Plus
(TIBCO Software, Palo Alto, California). The most widely used software today for the
characterization of PopPK, however, is NONMEM® (distributed by ICON Development
Solutions, Ellicott City, Maryland).
Application of modeling and simulation in pediatrics
The modeling and simulation (M&S) approach has been widely used in all phases
of drug development and drug evaluation, from preclinical to post-marketing
(Figure 1-3) [77]. Today it has become an integral part of the drug development process
and regulatory decision making [78]. In a review of 198 submissions between 2000 and
2008 to the US FDA [79], the number of cases involving M&S analyses (pharmacometric
approach) had increased 6-fold over 9 years. Among them, 26% of the submissions
included pediatric studies.
The core component of pediatric studies is to provide optimized dosing regimens
for safety and efficacy with both new and established medications. On the one hand,
scientific-based drug development and pharmacotherapy are greatly needed and have
been mandatory by legislation [80]; on the other hand, pediatric studies are hampered to a
great extent by ethical, medical and practical issues. The advantages of M&S are to give
added value to pediatric drug studies for its ability to overcoming such challenges in this
population group. Due to recent regulatory incentives for the conduct of pediatric studies,
population-based M&S plays an increasingly important role in pediatric drug
development [81]. In the current work, we focus on the effect of population-based M&S
on data analyses, sample size estimation and selection of dosing regimens.
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Figure 1-3. Potential applications of modeling and simulation concepts during
preclinical and clinical drug product development
Source: Reprinted with permission. Meibohm, B. and H. Derendorf, Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci, 2002. 91(1): p. 1831.
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Population-based modeling: sparse and unbalanced sampling
As we discussed, one of the specific advantages of population-based M&S is the
capability of handling sparse and unbalanced data from a large, heterogeneous group of
patients, which is the situation in neonates and infants studies [73]. Because of ethical
and medical concerns, young children are well protected by minimizing the invasive
samplings and all blood specimens are usually only collected for a therapeutic or
diagnostic purpose. Therefore, the number of blood samples from each individual is very
limited and usually doesn’t follow a fixed sampling schedule. The successful application
of M&S makes the study of this critically ill population (NICU patients) more feasible. A
number of PopPK studies were conducted in children using sparse data with unbalanced
design, or they took advantage of therapeutic drug monitoring (TDM) data, and the
developed models and results were successfully translated into clinical therapeutic
decision making, thereby benefitting patients with optimal dosing regimens. Some of the
examples include vancomycin [82-84], phenytoin [85], midazolam [86], aminoglycosides
(gentamicin, tobramycin, netilicin, amikacin) [87] and sotalol [24]. Identification of
significant factors contributing to the variability of parameters can be especially
important in premature infants where rapid developmental changes occur over relatively
short periods of time, resulting in a large variability in drug disposition. The developed
models can be used in the future for dosing regimen optimization by relating PK
parameters (such as CL) and patient demographic factors (such as body weight and, age)
to criteria for therapeutic safety and efficacy.
Clinical trial simulation
Clinical study designs can be explored by simulation based on PKPD modeling.
M&S as a powerful tool for rationale decision making provides the capability for careful
design and planning in pediatric studies. Clinical trial simulations closely depend on
population pharmacokinetics. They allow researchers and clinicians to explore situations
that have not been investigated before—thereby gaining insight into a “new world,” for
example, extrapolating results from animals to humans. Another advantage of clinical
trial simulations is to help researchers tailor design factors by comparing and
investigating simulation results as if in the “real world”—including, for example, optimal
sampling design for a trial, optimized sample size estimation, or optimized dosing
regimens. M&S provides a scientific framework for efficient decision making, thereby
increasing the probability of success in clinical studies while minimizing risk and cost.
Optimal study design
A carefully designed clinical study will improve the probability of “success” by
comparing and assessing the impact of different design factors that may affect the
outcome, such as dosing regimen, sample size, number of drop-outs and trial duration,
with considering uncertainties [88]. Sample size estimation is a key factor for a
successful study with adequate power and reliable results but involving a minimum
number of patients (sample size) in order to minimize the trial duration, cost, and the
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potential risk imposed to the patients. A minimum but adequate sample size is one of the
most important aspects of optimal study design in pediatric patients due to the ethical
limitations in this population. However, sample size estimation has not been included in
most population pharmacokinetic studies. Through the M&S based upon available PKPD
data and/or prior knowledge, the required number of subjects can be estimated to best
reflect the study objectives and characterize pharmacokinetics in specific populations.
We will illustrate this application in Chapter 3.
Rapid developmental change is another feature associated with pediatric patients,
especially with neonates and infants, which leads to large between-subject and withinsubject variability in premature neonates and infants. If developmental changes are not
included during the study design, the clinical trials are likely to fail due to the lack of
knowledge of drug action during the development process [68, 89]. Simulations coupled
with PopPK models allow testing the different designs and the impact of uncertainty on
the outcome of the study in a computer-based, virtual environment; they provide
researchers chance to gain insight into the results before the study is actually performed.
Mouksassi et al. [90] used PopPK and clinical trial simulations to select dosing regimens
for a phase I study of teduglutide in pediatric patients with short-bowel syndrome. In
their study, realistic covariate input specific to the targeted patient population was
simulated and used to evaluate dosing strategies under various age-weight,
pathophysiological conditions thereby determining safety and efficacy in this patient
population. Thus in the pediatric group, M&S is a useful tool to optimize the study design
by incorporating the growth effect and maturational changes, and maximize the
likelihood of achieving target exposure in the real clinical setting. Meanwhile,
appropriate sample size will ensure a successful study with fewer patients exposed to the
investigational procedures, which is also meaningful for the ethical and practical
considerations when conducting a pediatric clinical trial.
Optimal dosing regimen
Traditionally, approval of a new drug application by FDA was primarily
determined by reviewing the medical and statistical data. As described previously, an
important advance in clinical drug investigations is the incorporation of population-based
M&S into an approval decision [78].
Among all types of decisions making, the majority of cases were relevant to
dosing selection based on quantitative benefit-risk assessments. Today, pharmacometrics
allows for dosing regimens to be based on modeling and simulation analyses before they
are thoroughly studied in phase III clinical trials, or they are supported by
pharmacometric analyses as confirmatory evidence for supporting labeling information.
Modeling and simulation can be useful in establishing optimal dosing strategies
and increasing the successful probability of a clinical study. Empirical Bayes estimation
of individual pharmacokinetic parameters acquired by modeling analysis, combined with
individualized measurement, has been successfully applied in pediatric PK studies for
individual optimal dosing selection. Simulation of PKPD can be performed to predict the
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drug concentrations or responses under a “real world” condition with different dosing
regimens. Thus appropriate study design and dosing strategy can be proposed for
pediatric studies based not only on empirical assumptions but also on a model-based
approach, Figure 1-4 shows a schematic illustration of this approach. Such approaches
have been evaluated in multiple studies for regulatory decision making [91-93]. Clinical
trial simulation allows the utilization of population PK/PD models along with the
integration of study design, patient demographics and disease status. As a result, optimal
design can be selected and dosing strategy may be evaluated in various conditions. For
example, the approval of levofloxacin dosage to treat anthrax in children was based on
pharmacometric analyses with M&S since no clinical trials could be conducted with the
recommended dosing regimen [94].
Summary and Specific Aims
Research efforts focused on optimized dosing strategies for safe and effective use
of medications in premature infants is needed to improve our understanding of drug
disposition in this population group. The utilization of advanced analytical assays will
allow for pharmacokinetic studies of drugs commonly used in premature infants. The
aims of this present work were to investigate research strategies in the pharmacokinetic
study of drugs used in premature neonates and infants, including bioanalytic assay
development, trial design factor investigation, PopPK model development and dosing
regimen assessment. These processes were aimed at developing optimized dosing
regimens for premature neonates and infants.
In specific aim 1 (discussed in Chapter 2), to enhance our knowledge on
pharmacokinetics of commonly used drugs in premature neonates, we developed and
validated an LC-MS/MS method for the simultaneous determination of commonly used
medications in the NICU, including acetaminophen, caffeine, phenytoin, ranitidine, and
theophylline, in small volume human plasma specimens of 50 µL [95].
In specific aim 2 (discussed in Chapter 3), we explored sample size requirements
for observational PopPK studies in premature neonates and infants using theophylline as
a model drug. A full model-based simulation approach was applied with prior
information and between-subject variability and residual variability. We evaluated the
accuracy, precision and power of parameter estimation and also investigated the effect of
sample size on the detection of significant covariates.
For specific aim 3 (discussed in Chapter 4), we developed a PopPK model of
caffeine in premature neonates and evaluated the change of PK parameters throughout
infancy. The developed model was subsequently used for a dose-optimization study by
simulation, particularly to simulate the distributions of steady state concentrations at
different dosing regimens for various age/body size groups, which provided the rationale
for age/weight specific, optimized dosing regimens.
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CHAPTER 2. A TANDEM MASS SPECTROMETRY ASSAY FOR THE
SIMULTANEOUS DETERMINATION OF ACETAMINOPHEN, CAFFEINE,
PHENYTOIN, RANITIDINE, AND THEOPHYLLINE IN SMALL VOLUME
PLASMA SPECIMENS*
Introduction
Premature infants (gestational age less than 37 weeks) are considered a vulnerable
patient population due to their immaturity at birth. Born at different gestational ages, they
experience rapid growth and continuous developmental changes in body size and
composition as well as organ size and function. Different stages of maturation and
different maturational trajectories for the physiological and biochemical processes that
govern drug disposition (i.e., absorption, distribution, metabolism, and excretion) result
in tremendous inter-individual pharmacokinetic variability, leading to very disparate
responses to drug therapy [96, 97].
Acetaminophen, caffeine, phenytoin, ranitidine, and theophylline are widely used
in the pharmacotherapy of premature and term neonates. Acetaminophen, or paracetamol,
is an effective and widely used analgesic and antipyretic medication in infants [98].
Caffeine and theophylline are both used in the treatment of neonatal apnea in premature
infants [99-101]. Ranitidine is frequently used for the reduction of intragastric acidity in
conditions such as pathological gastro-oesophageal reflux or stress ulcer prophylaxis in
critically ill infants, the latter being a common side effect of steroid treatment in
premature infants with bronchopulmonary dysplasia [102]. Phenytoin is applied as a
second line medication for the pharmacotherapy of seizures in patients with treatment
failure on phenobarbital therapy [103]. Only limited information is currently available on
the pharmacokinetics of these medications in premature neonates. Ethical and practical
constraints in sample collection from this patient population limit the number and volume
of blood specimens available for pharmacokinetic evaluations [104].
In recent years, high performance liquid chromatography with mass spectrometry
detection (LC-MS/MS) has become the standard analytical methodology in
pharmacokinetic evaluations due to its robustness and high sensitivity. LC-MS/MS
allows for reliable drug and metabolite quantification even within the confines of small
sample volumes in pediatric studies [104]. A number of quantitative assays using
LC-MS/MS for the above mentioned drugs have been previously described. These
methods, however, are limited to the quantification of one specific drug per assay, and
many do not have sufficient sensitivity to quantify therapeutic drug concentrations in
small volume plasma specimens [61-67]. Due to the limitations in sample volume, only
*Adapted with permission. Zhang, Y., et al., A tandem mass spectrometry assay for the
simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and
theophylline in small volume pediatric plasma specimens. Clin Chim Acta, 2008. 398(12): p. 105-12.
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an assay that can simultaneously determine multiple drugs concurrently used in the
pharmacotherapy of premature neonates was deemed feasible to support pharmacokinetic
studies in this population. Thus, in the present study, we developed and validated an LCMS/MS method for the simultaneous determination of acetaminophen, caffeine,
phenytoin, ranitidine, and theophylline in small volume human plasma specimens of
50 µL.
Materials and Methods
Chemicals and reagents
All chemicals used including acetaminophen (C8H9NO2, 99.0%, MW 151.2),
caffeine (C8H10N4O2, 99.9%, MW 194.2), phenytoin (C15H12N2O2, 99%, MW
252.3), ranitidine hydrochloride (C13H22N4O3S٠HCl, >99%, MW 350.9), theophylline
(C7H8N4O2, >99%, MW 180.2) and the internal standard, phenacetin (C10H13NO2,
MW 179.2), were purchased from Sigma-Aldrich, Inc. (St. Louis, MO). Their chemical
structures are shown in Figure 2-1. HPLC grade water and methanol were acquired from
Fisher Scientific (Fair Lawn, NJ). Pooled human plasma was obtained from LifeBlood
Biological Services (Memphis, TN). All other materials were purchased from standard
vendors and were of the highest available quality.
Instrumentation
The LC system consisted of a Shimadzu high performance liquid
chromatographic system (Shimadzu Scientific Instruments, Norcross, GA, USA), coupled
with a HTC PAL autosampler (Leap Technologies, CTC Analytics, Carrboro, NC).
Chromatographic separation of acetaminophen, caffeine, phenytoin, ranitidine,
theophylline, and the internal standard was performed on a Phenomenex Luna® 3 μm
C18(2) column (50 mm x 2.00 mm, Phenomenex, Torrance, CA) with a gradient elution
using mixtures of water and methanol, mobile phase A (95:5, v/v) and mobile phase B
(10:90, v/v), both containing 0.05% formic acid. The optimum separation was achieved
by increasing mobile phase B from 0% to 80% in the time period of 0 to 3 minutes,
staying at 80% B from 3 to 5 minutes, and then dropping to 0 % B from 5 to 6 minutes.
The flow rate was 0.3 mL/min. Detection was performed using a MDS Sciex API 3000
triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) that was
operated in positive ion mode with turbo electrospray ionization. All analyses were
performed in the multiple reaction monitoring (MRM) mode. Instrument control and data
acquisition were performed using the Analyst v1.4.2 software package (Applied
Biosystems, Foster City, CA).
Optimization of the detection conditions was performed by direct infusion of the
analytes (1 µg/mL, dissolved in methanol) from a syringe pump into the mass
spectrometer. The auto tuning function of the Analyst software was used, and the
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optimized parameters were used for the simultaneous detection of acetaminophen,
caffeine, phenytoin, ranitidine, and theophylline. The parameter settings were as follows:
turbo ionspray gas 7 L/min, nebulizer (nitrogen) gas 4.00 psi, curtain gas 8.00 psi,
collision-activated dissociation gas 6.00 psi, ionspray voltage 5500 V, temperature
400 ºC, declustering potential 60 V, focusing potential 200 V, entrance potentials 10 V,
collision energy 30 V, and collision cell exit potential 12 V.
Calibration standards and quality control samples
Primary stock solutions of analytes and IS were prepared at 1 mg/mL in methanol
and stored at 20 ºC. 200 µg/mL working solution was prepared by combining equal
volumes of acetaminophen, theophylline, caffeine, phenytoin, and ranitidine stocks. The
highest calibrator at a concentration of 25,000 ng/mL was prepared by adding 125 µL of
200 µg/mL working solution into 875 µL of blank human plasma. Serial 1:2 dilutions of
the highest calibrator in blank human plasma was used to produce 12 standard calibration
samples with concentrations of 12.2, 24.4, 48.8, 97.7, 195.3, 390.6, 781.3, 1,562.5, 3,125,
6,250, 12,500, and 25,000 ng/mL. Internal standard working solution was diluted to
10 µg/mL in methanol. 1 mg/mL quality control (QC) standard solutions were prepared
separately. Quality controls were prepared by adding small volumes of stock solutions to
blank plasma. Three quality control levels at 100, 1,000, and 10,000 ng/mL were
prepared and utilized for all drugs. Calibrators and controls were freshly prepared before
each analysis.
Sample preparation
Sample preparation was performed by protein precipitation with methanol. 50 μL
aliquots of plasma from calibration samples, quality control samples, or plasma
specimens with unknown drug concentrations were transferred to 0.5 mL microcentrifuge
tubes. 175 μL of ice-cold methanol containing 10 μL of the internal standard (10 μg/mL)
was added to each tube. Samples were vortex-mixed briefly at high speed and kept on ice
for 40 minutes. The samples were then centrifuged at 14,000 g for 10 minutes at 4 oC.
Approximately 120 μL of the supernatant of each tube was transferred to an amber clean
autosampler vial with insert for analysis. 10 μL of the aliquot solution was subsequently
injected into the LC-MS/MS system.
Sample quantification
Concentrations of each analyte were determined based on the ratio of the peak
area for their monitored mass transition and the peak area of the mass transition
characteristic for the internal standard. A calibration curve covering the entire
therapeutically used plasma concentration range was established for each analyte using
linear regression analysis of the ratio of analyte peak area/internal standard peak area
versus analyte concentration with a weighting factor of 1/x. Unknown analyte
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concentrations were calculated from the calibration curve based on the measured peak
area ratios for the various analytes monitored.
Validation
The developed LC-MS/MS assay was validated for linearity, accuracy, precision
and recovery [105].
Linearity
Linearity was evaluated over the concentration range of 12.2 to 25,000 ng/mL for
all analytes. Calibration standards were prepared freshly in duplicate for three validation
runs on three separate days. The assay acceptance criterion for each standard
concentration was ± 15% deviation of the nominal concentration, except for the lower
limit of quantification, where a deviation of ± 20% was accepted.
Precision and accuracy
Precision was expressed as the percent relative standard deviation (%RSD) and
accuracy was expressed as percent error [18]. The intra-day and inter-day accuracies and
precisions of the assay were assessed by analyzing QC samples at three concentration
levels (100, 1,000, 10,000 ng/mL). Five replicates of each QC sample were analyzed in
the same batch and %RSD and percent error were calculated for each set of replicates per
batch to determine the intra-day accuracy and precision. This process was performed
three times over three consecutive days and %RSD and percent error were calculated for
all 15 replicates per QC sample in order to determine the inter-day accuracy and
precision.
Recovery and matrix effect
Recovery and matrix effect were assessed at three concentration levels (100,
1,000, and 10,000 ng/mL) for each of the analytes, comparing the peak areas of five
replicates at each concentration for analyte standards in methanol and standards spiked
before and after protein precipitation in human plasma [106-108]. Relative recovery was
expressed as the ratio of the mean peak area of an analyte spiked before extraction to the
mean peak area of the same analyte spiked post extraction in the same matrix multiplied
by 100. Absolute recovery was calculated as the ratio of the mean peak area of an analyte
spiked before extraction to the mean peak area of the same analyte spiked in methanol at
the same concentration multiplied by 100. The matrix effect was evaluated by comparing
the mean peak area of analyte spiked post extraction to the mean peak area of an
equivalent concentration of the same analyte standard in methanol.

23

Results and Discussion
Method optimization
The assay development to simultaneously quantify acetaminophen, caffeine,
phenytoin, ranitidine, and theophylline in small volume plasma specimens included
optimization of the MS/MS detection, the chromatographic separation and the sample
preparation procedures.
Based on the chemical structures of the analytes, an electrospray ionization
interface (ESI) was used for ion generation. A Q1 full scan of each analyte and IS was
acquired in both positive and negative mode when tuned under constant infusion at 600
μL/h of a 1 μg/mL methanol solution of the analytes. The signal-to-noise ratio was used
as the measure of sensitivity [109]. The positive ion mode of the ESI was selected for all
analytes and IS due to a greater sensitivity compared to the negative ion mode. The
protonated form of the analyte molecules [M + H]+ was monitored at m/z 152.2, 195.2,
253.3, 315.2, 181.3, 180.3 for acetaminophen, caffeine, phenytoin, ranitidine,
theophylline, and IS, respectively. Similarly, the most abundant product ion of each
analyte or IS was selected for observation in the multiple reaction monitoring (MRM)
scan. The mass transitions selected for quantitative analysis were m/z 152.2 to 110.2 for
acetaminophen, m/z 195.2 to 138.3 for caffeine, m/z 253.3 to182.3 for phenytoin, m/z
315.2 to 176.2 for ranitidine, m/z 181.3 to 124.0 for theophylline, and m/z 180.3 to 138.3
for phenacetin as IS. Figure 2-2 depicts the product ion scan spectra of each analyte and
the IS.
Due to the wide range in polarity of the five analytes, a single isocratic elution on
a C18 column did not result in chromatographic separation within an acceptable run time.
After evaluation of a variety of elution conditions, the separation, sensitivity, peak shapes
and retention time were found to be satisfactory when using a gradient elution with a
mobile phase of water and methanol containing 0.05% formic acid. All analytes and the
IS had retention times of less than 6 minutes and the total assay run time was 8 minutes
including the solvent equilibration time. Figure 2-3 shows a representative
chromatogram for a methanol solution containing 500 ng/mL of each analyte.
Assay performance
A chromatogram acquired from a blank human plasma sample spiked with 500
ng/mL acetaminophen, caffeine, phenytoin, ranitidine, theophylline is shown in
Figure 2-4. For all analytes, good linearity in the calibration curves was achieved with
correlation coefficients of R > 0.9985, or coefficients of determination of R2 > 0.997.
Figure 2-5 depicts calibration curves for each analyte.
For acetaminophen, phenytoin, and ranitidine, the assay allowed quantification in
a range of 12.2 to 25,000 ng/mL, for theophylline in the range of 24.4 to 25,000 ng/mL,
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Figure 2-3. LC-MS/MS chromatograms acquired from a standard methanol
solution containing 500 ng/mL analytes
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Figure 2-4. LC-MS/MS chromatograms acquired from blank human plasma
spiked with 500 ng/mL of analyte drugs
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and for caffeine in the range of 48.8–25,000 ng/mL. These ranges cover each drug’s
therapeutically used concentrations in the neonatal age group described as 4,000–20,000
for acetaminophen [110, 111], 5,000–12,000 ng/mL for theophylline [112, 113], 8,000–
20,000 ng/mL for caffeine [113], 6,000–15,000 ng/mL for phenytoin [103, 114], and
100–2,000 ng/mL for ranitidine [115-117].
The lower limit of quantification for each analyte was defined as the lowest
concentration on the calibration curve with the signal-to-noise ratio (S/N) > 10 and is
listed in Table 2-1. The upper limit of quantification was defined as the highest
concentration on the calibration curve. Precision and accuracy for each analyte are
summarized in Table 2-2. The mean accuracy ranged from 87.5 to 115.0% and the intraday and inter-day precision was between 2.8–11.8% and 4.5–13.5%, respectively.
As some of the clinically measured concentrations may exceed the upper limits of
quantification, a sample dilution procedure was also evaluated. The dilution procedure
was conducted in five replicates for acetaminophen, theophylline, caffeine and phenytoin
by using one half (25 µL) of the standard sample volume of plasma spiked with 50,000
ng/mL and 10,000 ng/mL of the analytes. All samples were diluted to 50 µL with blank
plasma and underwent the same sample processing procedure as previously described.
The intra-batch (within batch) accuracy and precision for the 1-to-2 dilution at both
concentration levels ranged from 89.8–110.9% and 1.6–10.4%, respectively (Table 2-3),
indicating that this dilution procedure can be applied to samples with very high analyte
concentrations.
Table 2-4 presents the summarized data for absolute recovery, relative recovery
and matrix effect. Since trace amounts of caffeine and theophylline were detected in all
blank plasma batches available to us, the matrix effect and absolute recovery for the low
and medium concentration range were not evaluated for these drugs. There was no
significant interference detected from the plasma for any of the other analytes or the
internal standard. Relative recoveries ranged from 85.6-118.3%, absolute recoveries
ranged from 67.3–103.5%, and matrix effect assessments ranged from 61.7–112.0% for
all of the analytes and the IS except ranitidine. Ranitidine showed a range of 105.4–
118.5% for relative recovery, 26.3–41.9% for absolute recovery, and 23.5–35.3% for
matrix effect. The high relative recovery suggests a good extraction efficiency of the
protein precipitation method for all analytes and the IS. Similarly, percentage values for
absolute recovery and matrix effect assessment were relatively high for all analytes
except ranitidine, suggesting only a minor effect on the signal intensity by ion
suppression from the matrix. Although ranitidine showed a relatively low absolute
recovery and a pronounced matrix effect for human plasma, the analytical method was
deemed acceptable for the intended purpose due to the satisfactory accuracy and
precision obtained within the quantification range of ranitidine.
We also evaluated the effects of hemolysis, lipemia and hyperbilirubinemia
(TBIL > 25 mg/dL and > 50 mg/dL) on the quantification of each drug at low (100
ng/mL), medium (1,000 ng/mL), and high concentration (10,000 ng/mL) levels. No
interference in the analysis was noted when these factors existed separately or combined.
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Table 2-1.
analyte

Calibration range and lower limit of quantification (LLOQ) for each

Analyte
Acetaminophen
Caffeine
Phenytoin
Ranitidine
Theophylline

Calibration Range (ng/mL)
12.2 - 25000
48.8 - 25000
12.2 - 25000
12.2 - 25000
24.4 - 25000
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LLOQ (ng/mL)
12.2
48.8
12.2
12.2
24.4

Table 2-2.

The accuracy and precision of the LC-MS/MS method for each analyte

Day 1

Accuracy
(%)
Day 2

Day 3

Intra-day
Precision
(%RSD)

Inter-day
Precision
(%RSD)

Acetaminophen

100
1000
10,000

97.8
90.7
87.5

96.9
109.8
108.8

102.6
102.6
94.6

10.2
10.8
5.3

10.0
13.0
10.9

Caffeine

100
1000
10,000

104.3
95.8
103.0

107.9
103.5
111.6

104.2
100.7
105.6

6.9
11.8
6.0

6.8
11.5
6.6

Phenytoin

100
1000
10,000

90.6
93.9
109.0

105.8
115.0
111.2

105.6
99.8
102.0

10.7
4.1
2.8

13.2
9.2
4.5

Ranitidine

100
1000
10,000

112.4
106.4
102.8

113.3
110.4
108.1

99.6
105.3
106

4.5
5.7
6.5

7.1
5.6
6.4

Theophylline

100
1000
10000

101.6
90.2
108.6

98.6
108.9
111.6

103.7
112.4
95.4

8.3
8.8
7.3

8.3
13.5
10.0

Analyte

Nominal
Concentration
(ng/mL)

31

Table 2-3.

Performance of a dilution procedure

Analyte

Dilution Factor

Acetaminophen
Caffeine
Phenytoin
Theophylline

Table 2-4.

10000 ng/mL

50000 ng/mL

Accuracy Precision

Accuracy Precision

1 to 2
1 to 2
1 to 2
1 to 2

107.5
110.9
109.6
97.9

7.1
8.7
4.7
10.4

89.8
93.1
107.3
103.7

2.6
2.0
1.6
2.0

Recovery and matrix effect

Analyte
Acetaminophen
Caffeine
Phenytoin
Ranitidine
Theophylline
IS (Phenacetin)

Relative Recovery
(%)
109.1-116.6
107.0-112.8
92.5-109.6
105.4-118.5
85.6-118.3
94.3-97.9

Matrix Effect
(%)
61.7-88.8
89.4*
72.7-110.5
23.5-35.3
80.7*
100.0-112.0

Absolute Recovery
(%)
67.3-103.5
96.2*
68.5-102.2
26.3-41.9
87.1*
94.2-102.0

* Since traces of caffeine and theophylline were detectable in blank plasma, matrix effect
and absolute recovery were evaluated only at the highest concentration level for these
analytes.
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In addition, we investigated the potential interference of high concentration differences
for analytes that are incompletely separated in the chromatographic process, particularly
acetaminophen, caffeine and theophylline. Tested molar ratios of up to 13:1 did not result
in any interference.
Figure 2-6 shows a representative LC-MS/MS chromatogram acquired from the
plasma sample of a human subject taking four of the drugs captured by our assay. The
analyzed concentrations were acetaminophen 7,010 ng/mL, theophylline 4,570 ng/mL,
caffeine 401 ng/mL, and ranitidine 432 ng/mL.
Conclusions
In summary, we developed a rapid, accurate, sensitive, and reliable LC-MS/MS
method to simultaneously quantify five drugs frequently used in the pharmacotherapy of
preterm neonates. The analyte quantification can be performed from small volume human
plasma specimens of only 50 μL, thereby facilitating an efficient use of limited blood
samples in pediatric patients. This bioanalytical assay is highly useful in supporting
clinical pharmacokinetic studies of these drugs in premature infants when combined with
population-based modeling and simulation techniques [9].
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Figure 2-6. A representative LC-MS/MS chromatogram acquired from a
subject’s plasma
(1) acetaminophen 7,010 ng/mL, (2) theophylline 4,570 ng/mL, (3) caffeine 401 ng/mL,
(4) ranitidine 432 ng/mL.
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CHAPTER 3. SIMULATION-BASED SAMPLE SIZE OPTIMIZATION TO
SUPPORT THEOPHYLLINE POPULATION PHARMACOKINETIC STUDY
DESIGN IN PREMATURE NEONATES
Introduction
In Chapter 1, we discussed the major challenges in conducting pharmacokinetic
(PK) studies in a pediatric population. Generally, ethical and practical concerns hamper
clinical studies in premature infants as compared to adults and older children. The core
problem is a lack of sufficient data for PK analysis due to the limited number of blood
samples available per patient and the limited number of available patients. Chapter 2
describes an accurate and sensitive LC-MS/MS assay that was developed and validated
for PK studies in premature infants. The presented bioanalytical assay allows for
simultaneous quantification of five frequently used drugs from a single plasma sample as
small as 50 μL. Therefore, this assay provides an opportunity for clinicians to assess the
PK of multiple drugs in premature infants simultaneously, which is valuable in expanding
our knowledge of PK in this population. Modeling and simulation is another effective
tool in pediatric PK studies. It allows researchers to explore “what if” scenarios and
therefore facilitates the optimization of study design in drug development and applied
pharmacotherapy in terms of sampling scheme (the time and number of blood samples
collected per patient) and sample size estimation (minimal number of subjects needed
under the given sampling scheme), resulting in a reduced need for experiments and
invasive study procedures. In this chapter, a full model-based, optimal-sample-size
estimation for a population pharmacokinetic (PopPK) study is presented. Theophylline
was used as a model drug in the current study. The results may be applied in future
PopPK studies in premature infants with drugs commonly used in the neonatal intensive
care unit (NICU).
Specific sampling design in pediatric studies
The aim of a pediatric study to characterize the PK disposition of drugs
commonly used in preterm infants is to ultimately use this information to guide an
individualized dosing strategy. To minimize the number of needed patients and the
procedures needed with each individual in this vulnerable population, an optimum
clinical trial design is desirable. However, a well-designed clinical study with an optimal
preplanned blood sampling schedule may not be practical and ethical in the NICU setting,
since research in this study population can only be performed within the context of
therapeutically necessary interventions, thereby limiting the available volume, frequency
and timing of PK blood sampling. Thus, the data collected from routine therapeutic drug
monitoring (TDM) have been suggested as an alternative for a PK study [118, 119]. One
major restriction using the data from routine TDM is that most concentration
measurements are from trough levels, therefore lacking information for the estimation of
volume of distribution [120], which mainly determines the loading dose of a drug
treatment. Since a small quantity of (50 μL) plasma is sufficient for an assay quantitation
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of drug concentrations, the open question is whether an aliquot from leftover routinely
obtained blood samples can be utilized in PK studies. A NICU patient usually undergoes
frequent routine laboratory assessments for complete blood count and biochemical tests.
In some critical situations, blood gas, electrolytes, and blood glucose are also monitored
as frequently as every one hour for the purpose of therapeutic guidance. We thus
hypothesized that any available leftover samples from those diagnostic blood samples
plus TDM data could be used for PK evaluations. One of the advantages of this study
design, which uses an opportunistic sampling approach as opposed to a more traditional
preplanned PK approach, is that no extra blood draw will need to be imposed on the
patients, therefore minimizing patient risk. Meanwhile the potential gain in knowledge of
specific drug disposition will significantly extend our understanding of drug therapy in
extremely premature infants. It is expected that over the course of the study, the sampling
times are variable among the patients and the number of concentration measurements per
subject will vary as well due to the different clinical requirements for blood specimens.
Therefore, both sparse and dense samplings with random sampling time allocations for
different drugs are expected in this study. In this particular case, we asked the question
how many patients are minimally required for a PopPK study to ensure accurate
estimation of the relevant model parameters to reliably detect clinically meaningful
differences.
Sample size and population pharmacokinetics
Population pharmacokinetics (nonlinear mixed effect modeling)
The population pharmacokinetic (PopPK) approach, using nonlinear mixed
effects modeling, allows for the simultaneous analysis of pooled data from multiple
patients and provides population-typical as well as individual PK parameter estimates.
One popular tool for PopPK analyses is the NONMEM® software. The term PopPK is
used synonymously with nonlinear mixed effects modeling today. It has been frequently
applied in pediatric studies due to the ability to extract information from sparse and
unbalanced sampling data [11, 76, 121].
Sample size for PopPK
Inefficient sampling design and unsuitable sample size may lead to a failed
population pharmacokinetic study [122]. Although it is always favorable to acquire
parameter estimations from a large sample size, the key is to determine the minimum but
adequate number of subjects needed to balance the study cost and duration, and to ensure
a study with adequate power. Sample size has been demonstrated to be one critical
determinant. Its calculation for analyses in nonlinear mixed effects modeling has not been
clearly defined. A number of publications suggested sample size determinations for
PopPK studies. Those proposed methodologies were either formulae based by using the
Wald statistic with first-order linearization of the nonlinear mixed effects model [123,
124] or simulation based on the likelihood ratio test or a confidence interval (CI)
approach [125, 126]. All of these studies determined the minimum sample size needed
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for detecting some level of difference for a parameter between two subpopulation groups
based on a prespecified hypothesis test, i.e., determining sample size as a function of
statistical power and clinically meaningful effect size (together with a given type I error
probability). For example, the hypothesis to be tested could be: is clearance in group one
15% lower than that in group two? How many subjects do I need to detect this
difference? How many subjects do I need if the difference in clearance is 30% or 40%?
Usually only the primary model might be involved, and some categorical covariates (such
as gender groups, two or more age groups) might be investigated as a subgroup.
In contrast, our study focused on two issues. The first was to estimate the typical
population pharmacokinetic parameters and their between-subject variability with certain
levels of accuracy and precision. Secondly, we wanted to assess and identify potential
covariates, that are significant predictors of pharmacokinetic parameters, such as CL and
volume of distribution [72]. Accordingly, the major concerns of sample size
determination in such studies should not focus on testing hypothesis or detecting the
differences in parameters between subgroups. Instead, sample size estimations would be
carried out for the purpose of a successful PopPK study: how many subjects should be
recruited so as to (1) obtain parameter estimations in the model with adequate accuracy
and precision; (2) reliably determine covariate effects by separating a covariate model
from the base model or its nested covariate model. Ogungbenro and Aarons [127]
proposed a confidence interval approach for the sample size determination of a PopPK
study when there is no clear hypothesis to be tested. In the current study, we attempted to
extend the application of this approach to explore the impact of sample size on the
quantification of continuous covariate effects (weight and age) in premature infants. In
our study, given a more complicated study design in premature infants, time-dependent
covariates and randomized sampling design were included; dose levels, sampling times
and number of concentrations per subjects were different for different patients. We here
present a full model-based sample size estimation using a simulation approach.
Objective
This simulation study was to explore sample size requirements for observational
PopPK studies in premature infants using theophylline as a model drug. It took prior
information (model, parameter estimates, between-subject variability and residual
variability) to identify a sample size that could provide unbiased and precise estimates for
the fixed and random effect parameters and covariate effect determination.
Methods
Overview of methodology
Figure 3-1 illustrates how the simulations were conducted to assess different
sample sizes for their ability to yield meaningful results given the same PopPK study
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Figure 3-1.

Overview of the methodology of the simulation and estimation steps

This figure details how the simulations were conducted to assess the designs and their
results.
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design. Main steps included:
•

SAS 9.1 was used to generate the datasets, including covariates and dosing
history.

•

200 independent datasets for each sample size (9-200 subjects per study) were
simulated.

•

A previously established population pharmacokinetic model and model
parameters were employed to simulate all concentration datasets. The step was
accomplished by using NONMEM version VI, Level 2.0 (ICON Development
Solutions, Ellicott City, Maryland) with GNU Fortran 77 (g77) version 2.95 (Free
Software Foundation, Cambridge, Massachusetts).

•

The PopPK model used for concentration simulation was applied to perform
re-estimation. Parameter estimates were then obtained for each dataset.

•

The process was repeated with 200 independent datasets. Median and 95%
confidence intervals (CIs) were then obtained for each parameter from 200
estimates.

•

The bias (accuracy) and precision in the estimates of the population mean PK
parameters and variance components were evaluated.

•

The impact of sample size on the parameter estimations in the model was
evaluated based on the proportion of the total number of simulations where the
estimated parameter values would fall inside a pre-specified interval considered
“close enough” to their respective true value.

•

Power to detect two continuous covariates, body weight and postnatal age, was
calculated as a fraction of tested statistics obtained in total number of simulations.

From the literature review, drugs of interest, such as caffeine, theophylline,
acetaminophen and phenytoin, all exhibited one compartment disposition model, with age
and weight being the two most important covariates of clearance and volume of
distribution [85, 128-130]. Therefore, a one-compartment model was considered to
examine the influence of sample sizes on the parameter estimation; weight and age were
used to illustrate the covariate effect determination in the PopPK study.
Datasets and simulating study design
Simulated datasets containing demographic data, dosing histories and sampling
times were generated using SAS version 9.1 (SAS Institute, Cary, North Carolina).
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Covariate simulation: demographic variables
Demographic variables, including birth weight (BW) and postnatal age (PNA) at
the entry time (PNA0), were generated by randomized uniform distribution based on
defined ranges in published data [131]. Postnatal age ranged between 1 and 25 days at
entry time into the study. Birth weight ranged from 400 g to 1500 g. Considering the fact
that premature neonates might be born at different gestational ages, no correlation was
given between PNA0 and BW. PNA was then derived from PNA0, and body weight
(WT) derived from BW and PNA according to biologically rationale development curves
through the 14-day sampling window, using published growth behavior [132]. Thus
PNA0 (days) ~ U (1, 25)

BW (g) ~ U (400, 1500)

Where U (a, b) refers to a uniform distribution with lower (a) and upper (b) limits.
Dosing history
All subjects were simulated to receive orally administered theophylline with a
loading dose of 6 mg/kg followed by maintenance doses of 3 mg/kg every 12 hours for
14 days.
Pharmacokinetic samplings
The simulations assumed that future population studies in premature infants will
be conducted with an opportunistic sampling approach as opposed to a more traditional
pharmacokinetic approach. A mixed and unbalanced sampling design (both sparse and
rich sampling) was included. All sampling times were simulated as random occurrences
rather than a pre-planned sampling scheme as only blood samples drawn for clinical
purposes would be used in the study. For each design (sample size), one third of
individuals supplied 2 sampling measurements, one third supplied 4 measurements, and
the remaining one third provided 8 sampling points.
Simulation scenarios
Sample sizes of 9, 15, 20, 40, 60, 80, 100, and 200 patients per study were
simulated. For each sample size, 200 independent datasets were generated under the same
condition.
Pharmacokinetic model and statistical model
Theophylline was used as a model drug to illustrate the method described in this
section. A previously established population pharmacokinetic model with model
parameters for both fixed and random effects was used in the evaluation [131]. The PK
model was described by a one compartment model with first order absorption and first
order elimination. The population pharmacokinetic model, parameterized in terms of
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clearance (CL), volume of distribution (V) and bioavailability (F1), was as follows:
TVCL (mL/hr) = θ 1 * WT (g) + θ 2 * PNA (days)
TVV (L) = θ 3 * WT (g)
TVF1 = θ 4
Where TVCL is the population typical value of clearance, TVV is the population
typical value for volume of distribution, and TVF1 is the typical population value for
bioavailability. θ 1 is the coefficient for the effect of WT on CL. θ 2 is the coefficient for
the effect of PNA on CL and θ 3 is the coefficient for the effect of WT on V. Following
literature, we assume these parameters to be θ 1 = 0.0123, θ 2 = 0.377, θ 3 = 0.000937 and
θ 4 = 0.918 [131].
The between-subject variability (BSV) of the population typical value of CL and
V was expressed by proportional error models as follows:
CLj = TVCL * (1+η CL,j )
V j = TVV * (1+η V,j )
η CL,j , η V,j ~N (0, ω2)
Where CLj and V j are parameter estimations for the jth individual in the study.
η CL,j and η V,j represent random variables normally distributed with zero means and
variances of ω CL 2 and ω V 2, respectively. ω CL 2 and ω V 2 can be estimated by NONMEM
and represent the between-subject variability in the population.
Residual variability was described by an additive error model as follows:
C obs,ij = C pred,ij + ε ij
ε ij ~N (0, σ2)
Where C obs,ij is the ith observed concentration in the jth subject, C pred,ij is the ith
model predict concentration in the jth subject and ε ij is the deviation of C obs,ij from
C pred,ij . ε ij is a normally distributed random variable with an average value of 0 and
variance of σ2.
Simulation values of between-subject variability of CL and V in terms of
coefficient of variation (CV %) were set at 15% on clearance and 43.5% on volume of
distribution --the same as the estimates reported in the original publication [20]. The BSV
on bioavailability F1 was set at 0. Residual variability in terms of standard deviation was
set at 1.93 mg/L, representing the differences between the observed and predicted
concentrations in the study population [131].
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Simulating concentration profile
Using the pharmacokinetic model described above and all the parameters for both
fixed and random effects, concentration profiles for theophylline in premature infants
were simulated with nonlinear mixed effect modeling, as implemented in NONMEM VI,
using the first order conditional estimation (FOCE) method.
Data Analysis
Parameter estimation
For each specified sample size, 200 replicates (or independent datasets) were
analyzed. The model described earlier was fitted to all the datasets. For each replicate
dataset, fixed effect parameters θ 1 , θ 2 , θ 3 and variability parameters ω CL , ω V and σ were
re-estimated by NONMEM VI using the same model. Bioavailability parameter θ 4 was
fixed since exclusive oral data was simulated in this study. First-order conditional
estimation method was used in all cases throughout the study. Approximately 2-15% of
estimation runs in each study experienced terminated minimization with reported
parameter estimates; these model-fitting processes were repeated with adjusted initial
estimates. This procedure did not necessarily lead to successful convergence. However, at
least 90% of the 200 simulation runs converged successfully for each study. All reported
parameter estimates, including those from terminated minimizations, were used in the
analysis. This procedure was carried out in each study design, with a sample size of 9, 20,
40, 60, 80, 100, and 200 subjects per study.
The parameters obtained from the 200 simulation datasets for each sample size
were compared with the numbers used in the concentration simulation step to assess the
bias and precision in the estimates of the population mean PK parameters and variance
components. Median parameter estimates were compared to the ‘true’ parameters of the
originating model, and 95% CIs for 200 replicates of each study were determined and
evaluated by visual inspection [122] to detect trends in the results. Mean prediction error
(%MPE) and root mean square error (RMSE) were computed as indices of accuracy and
precision using the following formula:
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Where n = number of simulations (n = 200), 𝑃𝑃�𝑗𝑗𝑗𝑗 is the value of parameter P k
estimated in the jth simulation and P k is the criterion value of parameters, representing
both fixed- and random-effect parameters.
In order to assess whether a certain number of subjects (sample size) is enough to
capture the true value of the parameter P k in the PopPK study under the given
opportunistic sampling design (blood samples collected per subject), the propensity of the
resulting parameter estimates to fall within pre-specified narrow intervals containing the
true parameter values was also investigated for each sample size. Typically, the statistical
power of a hypothesis test is defined as the probability that we correctly reject the null
hypothesis when a certain minimal effect size (deviation of the true value from the value
assumed under the null hypothesis) is indeed present (equivalent to 1- β = 1- probability
of a Type II error). In a simulation study, statistical power is typically not determined by
formula-based computations but determined by the percentage of correctly rejected null
hypotheses in repeated computer experiments that emulate certain realistic study settings
[133]. In the current study, we compare the estimated parameter 𝑃𝑃�𝑗𝑗𝑗𝑗 to the criterion
parameter from the literature, P k , (the ideal ratio of 𝑃𝑃�𝑗𝑗𝑗𝑗 to P k is 1 if 𝑃𝑃�𝑗𝑗𝑗𝑗 coincides with the
true parameter value). If a difference > 20% (20% precision level) is determined to be
significantly different, a range of 0.80-1.25 for the ratio is an acceptable criteria based on
the two one-sided tests procedure [134]. That means if the ratio of 𝑃𝑃�𝑗𝑗𝑗𝑗 / P k falls in the
range of [0.80, 1.25], we considered the true parameter could be accurately estimated at
the 20% precision level (i.e., would be reproducible for practical purposes). Note that this
procedure is somewhat similar to the traditional “power” concept but has important
distinctions; most notably we compare the obtained ratio to a pre-specified interval of
acceptable values, and hence do not compute a confidence interval that would vary in
each iteration of the simulation as is the case in statistical hypothesis testing.
Furthermore, we are interested in how often we estimate the parameter “close enough” to
the true value when simulating from this true model and do not evaluate how often we
reject a certain value when the true model indeed differs in a particular way as would be
the case when determining traditional power of a study. We proceeded as follows: For
each investigated sample size, 200 ratios were obtained from the 200 simulations. The
relative success of our computer experiments (”power”) were computed as the number of
times we “correctly” identified the parameter value (estimate within the pre-specified
values) divided by 200. Namely, the percentage of the 200 ratios that fell within the
limits of 0.80-1.25 is referred to as the relative success (“power”) of the study. This
procedure was also repeated at precision levels of 30% and 40% for parameter
estimations with the corresponding ranges of [0.70, 1.43] and [0.60, 1.67] for the 𝑃𝑃�𝑗𝑗𝑗𝑗 /P k
ratios.
Covariates effect determination
The impact of sample size on covariate effect determination was investigated
through comparison of objective function values (OFV) of a covariate model and its
nested model in 200 replicate datasets. OFV is proportional to -2 log likelihood of the
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data and is a global measure of goodness of fit. Postnatal age and body weight were
selected as the predictors of clearance, and body weight was selected as the predictor of
volume of distribution [131]. Model improvement when including one covariate was
evaluated based on chi-square distribution with one degree of freedom. A statistically
significant model improvement was associated with a decrease of OFV by 3.84 when
P = 0.05. More stringent criteria commonly used are χ2 1, 0.01 = 6.64 and χ2 1, 0.001 = 10.83. To
be conservative, estimation runs with failed convergence were repeated with adjusted
initial estimates until successful minimization was gained in all 200 replicates. Model
separation was based on the decrease of objective function values (∆OFV) at 3 levels
(i.e., P = 0.05, P = 0.01 and P = 0.001).
For each proposed sample size design, power was determined by calculating the
fraction of simulations that ∆OFV achieved or exceeded the prespecified criteria for at
the three significance levels.
Results
Dataset generation
Based on a reported longitudinal postnatal growth study in very low birth weight
infants [132], average daily weight gain in g/day varied across 100-g birth weight
intervals, ranging from 15.27 to 27.77 g/day. Gestational age, race and gender had no
significant influence on the growth rate within each 100-g birth weight interval. So the
average daily increments stratified by 100 g birth weight interval (Table 3-1) were
employed to compute the body weight gain in the simulation.
An example for the mixed, unbalanced and randomized sampling design is shown
in Figure 3-2. The representative study had included 9 simulated subjects with 42
concentrations; of them, 3 subjects contributed 2 concentration measurements, 3 subjects
contributed 4 concentration measurements, and the other 3 subjects contributed 8
concentration measurements. The sampling allocation time ranged from 0.5 hr to 329 hr
post loading dose within 14 days (336 hr) treatment. The sampling time spread between
any two concentration measurements for each subject ranged from 2 hr to 237 hr, with a
median of 32 hr. All sampling times were simulated as random occurrences over a 14-day
sampling window, representing the paradigm of flexible blood sampling performed at any
time. It should be noted that all datasets were generated independently so that the
descriptive statistics for sampling time and demographic information, such as PNA and
birth weight, varied in the simulations of the 200 different studies.
Precision and accuracy of parameter estimation
The mean parameter estimates of the 200 simulations using sample sizes of 9, 15,
20, 40, 60, 80, 100 and 200 subjects are presented in Table 3-2. Under the given study
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Table 3-1.
Average daily increments (g/day) used for body weight calculation
stratified by birth weight interval
Birth Weight Interval (g)

Weight Gain (g/day)

≤ 600
601-700
701-800
801-900
901-1000
1001-1100
1101-1200
1201-1300
1301-1400
1401-1500

15.27
16.81
18.6
20.06
21.04
22.83
24.73
26.34
27.15
27.77

Source: Modified with permission. Ehrenkranz, R.A., et al., Longitudinal growth of
hospitalized very low birth weight infants. Pediatrics, 1999. 104 (2 Pt 1): p. 280-9.
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Figure 3-2. A representative study showing the mixed, unbalanced and
randomized samplings from a 9-subject study
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Table 3-2.
Central tendency (median parameter) of estimates for the simulations
at different sample size
Sample Size
Criterion
Value
9
15
20
40
60
80
100
200

θ1

θ2

θ3

ω CL

ωV

σ

0.0123

0.000377

0.000937

0.0226

0.189

3.72

0.0120
0.0124
0.0121
0.0126
0.0128
0.0126
0.0126
0.0127

0.000366
0.000365
0.000381
0.000358
0.000357
0.000365
0.000370
0.000357

0.000909
0.000931
0.000911
0.000931
0.000909
0.000927
0.000912
0.000918

0.0110
0.0174
0.0181
0.0196
0.0216
0.0209
0.0223
0.0220

0.099
0.149
0.150
0.156
0.156
0.161
0.157
0.161

3.69
3.57
3.65
3.74
3.72
3.75
3.76
3.77
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design, median parameters were well estimated across all sample size groups. When
visually inspected, 95% CIs of PopPK parameters as measure of precision converged as
sample size increased and became much narrower and remained stable when the sample
size was > 60 (Figure 3-3).
The %MPE results are shown in Table 3-3 and illustrated in Figure 3-4. A
smaller %MPE value indicates an on average smaller (relative) deviation of the estimated
parameter value from the true value (preferable). All sample sizes gave unbiased
estimates for all parameters except for two variability parameters, BSV on clearance
estimation (ω CL ) and BSV on volume of distribution estimation (ω V ). %MPE was below
5% for θ 1~3, and σ estimations at all investigated sample sizes except for one estimate of
θ 2 showing as -6.2%. Substantial bias in variance of between-subject variability for V and
CL (ω CL ω V ) is noted for small sample sizes. %MPE as large as -33% for ω CL, and -32%
for ω V was observed at sample size of 9; but dropped to -6.5% and -6.2%, respectively,
when sample size increased to 40, indicating a marked increase in accuracy with
increasing sample size. The bias for ω CL and ω V estimations was entirely negative, while
both positive and negative biases were observed for other parameters in the model.
Optimal sample size was evaluated by assuming a percentage coefficient of variation
(CV%) at 15% for CL and 43.5% for V. Histograms of CV % for CL and V by different
sample size are shown in Figure 3-5 and Figure 3-6. The results suggest that a
substantial improvement in the estimation of variance parameters is correlated with an
increased sample size.
The results of RMSE for the simulations are presented in Table 3-4, and its CV%
is illustrated in Figure 3-7. RMSE generally decreases in all parameter estimations as the
sample size increases, indicating increasing precision with increasing sample size. For a
given sample size, the estimations of fixed effect parameters are better than those of the
random effect parameters. The number of subjects does not seem to have as significant an
influence on the precision of parameter estimations as long as it reaches 40 for fixed
effect parameters and 60 for covariance parameters.
The influence of the number of subjects on the relative success of the study as
defined here (“power”) was also investigated. Plots of relative success against sample
size at various precision levels are presented in Figure 3-8. With our randomized
sampling design, the relative success of our parameter estimation was deeply influenced
by sample size, parameter of interest and the selected precision level. For example,
assuming 20% difference was allowed in parameter estimation, a study would require 20
subjects to give in 80% of the cases “close enough” estimates for θ 1 , while at least 100
subjects would be required to achieve the same performance for θ 2 under the current
sampling and study design. A relatively high success rate (≥ 0.8) was shown in all sample
sizes for 30% (ratio limit 0.70-1.43) and 40% (ratio limit 0.60-1.67) precision levels for
θ 1 , θ 3 and σ. The number of subjects required for θ 2 also dropped to 40 and 20,
respectively, at those two levels. The success rate of estimating the BSV parameters ω CL
and ω V was much lower compared to the other parameters (Figure 3-9). To obtain
successful estimation with a probability > 0.6, 20, 40 and 200 subjects in each study were
considered to be sufficient at a precision level of 40%, 30% and 20%, respectively.
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Figure 3-3. Median and 95% CIs for PopPK parameters and variance
parameters from 200 simulated datasets
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Table 3-3.

%MPE of parameter estimates with various sample sizes

Sample Size

θ1

θ2

θ3

ω CL

ωV

σ

9
15
20
40
60
80
100
200

-1.884
1.153
-0.373
1.799
3.463
2.898
2.600
3.172

4.265
-1.638
4.229
-2.621
-6.229
-3.789
-2.385
-4.711

0.684
0.432
-0.584
-0.755
-3.126
-1.170
-3.152
-1.767

-33.054
-19.287
-15.043
-6.486
-2.591
-2.525
2.212
-1.473

-32.119
-10.914
-13.471
-12.401
-12.428
-6.966
-9.565
-7.221

1.036
-1.813
-0.370
3.739
0.780
0.667
1.816
2.829

Figure 3-4.

Accuracy of parameter estimates in different sample size groups

Bias is expressed in terms of %MPE.
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Figure 3-5.
subjects

Estimated BSV on population CL in terms of CV% vs. numbers of

The red dash line indicates the CV% = 15%.
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Figure 3-6. Estimated BSV on population volume of distribution in terms of
CV% vs. numbers of subjects
The red dash line indicates the CV% = 43.5%.
52

Table 3-4.

RMSE of parameter estimates with various sample sizes

Sample Size

θ1

θ2

θ3

ω CL

ωV

σ

9
15
20
40
60
80
100
200

0.00293
0.00263
0.00215
0.00143
0.00128
0.00123
0.00102
0.00082

0.00020
0.00016
0.00014
0.00009
0.00008
0.00007
0.00006
0.00005

0.00022
0.00018
0.00016
0.00011
0.00010
0.00010
0.00009
0.00005

0.01849
0.01836
0.01227
0.01084
0.00637
0.00740
0.00775
0.00427

0.13761
0.15037
0.12270
0.10307
0.08464
0.09251
0.09318
0.05675

0.96455
0.74605
0.65776
0.84215
0.47897
0.38901
0.40640
0.35409

Figure 3-7.

Precision of parameter estimates in different sample size groups

Precision is expressed in terms of CV%.
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Figure 3-8. Sample size vs. success rate in parameter estimation (“power”) at
different precision levels of 20%, 30% and 40%
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Figure 3-9. Sample size vs. success rate (“power”) at different precision levels of
20%, 30% and 40% for each estimated parameter in the model
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Covariate effect determination
The power to detect a covariate effect was determined by comparisons of
objective function values for the analyses of 200 independent datasets. Objective function
value comparisons were made between the structural base model and the covariate model
under different sample sizes and three different significance levels. Figure 3-10 shows
the power to detect three covariate effects: body weight on CL, postnatal age (PNA) on
CL, and body weight on volume of distribution. Being the most important size covariate
for pharmacokinetic parameters in pediatric population, weight can be detected with a
higher power using a relatively small sample size. To detect the effect of weight on CL
with power of 0.8, 9 subjects would be needed at the level P = 0.05; and 15 subjects
would be sufficient at a more stringent level of P = 0.001. The sample size (with
significance level) required for the detection of all three covariate effects with power >
0.8 were 20 (P = 0.05), 40 (P = 0.01) and 60 (P = 0.001), respectively.
Discussion
A well determined sample size for a clinical study based on a specified design is
considered ethical by limiting the required number of patients while increasing the study
power. PopPK studies have the potential to fail by providing unreliable results due to an
inadequate study design and a low statistical power. To include the right number of
patients is key to solving this problem. To date, most traditional approaches to sample
size determination are based on hypothesis testing: A certain degree of difference in PK
parameter estimations must be specified beforehand, and then the sample size needed to
detect this difference between two or more subgroups is calculated based on Type I and
Type II error levels [135-137]. The impact of sample size on the detection of the
relationship between covariates and PK parameters has also been studied. Potential
covariates were investigated only as categorical factors, such as gender, race, binomial
response, age brackets or other category of variable [123, 126]. For PopPK studies in
pediatric populations, the concerns are usually regarding the precision and bias of the
obtained estimates, instead of a hypothesis or the statistical differences between the
parameter estimations. Also, the impact of age and size as continuous covariates on the
PK parameters is of great interest. Therefore, we believe the full model-based simulation
approach presented here is a more appropriate method for sample size estimation in
PopPK studies.
Population pharmacokinetic studies in premature infants have special aspects that
must be taken into account for a rational and ethical design. In young pediatric patients,
the number of blood samples from each patient and sampling times usually cannot be
controlled and predetermined due to therapeutic constraints under which the study is
performed. Taking advantage of an aliquot from leftover from blood specimens drawn for
therapeutic purposes may be a new way to generate pharmacokinetic information while
minimizing patient risk. This sampling strategy determines that the number, and
allocations of blood samples collected from each patient, will not be identical. The
population modeling process forms the basis for analyzing sparse and unbalanced data
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Figure 3-10. Sample size effect on power to detect covariate effects
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from multiple patients. Although there has been no such experience on sample size
estimations based on an opportunistic blood sampling design in premature neonates
group, the model-based simulation approach allows us to explore the impact of sample
size on the performance of a PopPK study with fixed model properties. We can optimize
the experimental process by comparing and evaluating the predicted outcomes from
various designs that cannot be practically explored through clinical testing, thereby
facilitating decision making [68].
One potential limitation of clinical trial simulations is the reliability of the prior
information included in the analysis. In the current study, the set of covariates generated
for each simulated individual should adequately reflect the “real world.” Size and age are
two important time-varying covariates in neonatal studies that play significant roles in the
prediction of individual pharmacokinetic behavior (CL and Vd). Unlike adult studies,
multiple-dose studies with neonates cannot neglect characterizing the infants’ changes in
size even for a short time. In addition, another fixed effect, dose, is also based on the
change in body weight. Due to the lack of a demographic database for research in
premature infants with very low birth weight, creating datasets with physiologically
reasonable covariates was the first challenge. To account for the difference of growth
velocity in body weight, all subjects were stratified by 100 g birth weight intervals. Prior
knowledge of longitudinal growth of very low birth weight infants was included in the
covariate model [132]. A reference growth chart was derived from 1,660 premature
infants whose birth weight and gestational age showed similar ranges to in our study.
Throughout the simulation procedures, mean parameter estimates for covariate effects
with our generated datasets were in strong agreement with the true values reported by the
publication used as reference for our PopPK model, suggesting that we successfully
created a physiologically reasonable virtual patient population of very premature infants.
However, from the available growth charts, anthropometric measurements for birth
weights under 500 g were not available. We therefore used the growth velocity for the
smallest available birth weight interval of 501 to 600 g for all individuals with a birth
weight < 600 g. Another neglected aspect in our simulation was the fact that the body
weight simulation did not describe the physiological weight loss commonly observed in
newborns during the first week after birth. However, the average daily weight gain
partially, if not fully, accounted for this temporary weight loss. Moreover, through the
uniform distributed simulation, ~75% of the individuals were older than one week of
PNA and had already overcome the dip in weight. No significant effect was expected in
the results; though the assumptions made here might lead to a later bias in variance
component estimation, they were not a determining factor.
In this simulation study we examined 8 sample sizes from 9 to 200 with 200
independent datasets for each of them. Compared to existing methodologies used in
sample size determination for population pharmacokinetic studies, our study displays
some unique features. First, a mixed and unbalanced sampling scheme was proposed,
which means both sparse and intense sampling existed; the sampling time and the number
of samples from each subject were variable. This feature is close to the expected reality
of specimen sampling in our future studies in premature infants. Our study evaluated the
unusual sampling design through a series of simulations and guided the selection of an
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appropriate sample size based on an acceptable success rate of estimation in the sense of
“close enough” parameter estimation (similar to the traditional “power” concept but not
identical). Moreover, the current simulation study investigated power for continuous
covariates as predictors of pharmacokinetic parameters as a function of sample size.
Additionally, we performed more complex simulations to mimic the pediatric clinical
setting in the analysis, with time-variant covariates and body weight normalized dose
levels.
The simulation was fully model-based and took advantage of the estimation
methods in NONMEM VI. The fixed-effect PopPK parameters were generally well
estimated in terms of accuracy and precision across all tested sample sizes while
estimations in variance parameters had larger variability and were more often “off target”
compared to those in fixed effects. This finding was fairly consistent with results from
other studies [120, 127, 138]. The BSV estimates were all negatively biased except for
one value—ω CL when sample size = 100 (See Table 3-3 and Figure 3-4). The possible
reason is that all simulations were based on a model which was a simplified form of the
real system based on some assumptions. Failing to account for any variability in the
model may lead to considerable bias in estimations of variance components, especially
for the between-subject variability [136]. In this study, the magnitude of variability
employed in the concentration simulation process was derived from the true patients used
for original model development; however, we used another covariate model to generate
key covariates, which conserved the correlation between PNA and body weight during
the 14 days follow-up. These covariates were then used as input in the simulations of
longitudinal data and parameter re-estimations. Although the generated datasets
adequately characterized the major aspects of the real patient population, they do not
necessarily represent atypical patients and the large variability of the “real patients”. This
covariate model partially contributed to the inaccurate estimations of BSV parameters in
our study.
Considering the performance in parameter estimation and covariate effect
detection, the minimum sample size required for a theophylline study in premature
infants was determined by the desired precision of parameters of interest under a given
blood sampling design. If the bias in parameter estimations in terms of %MPE was set as
a cut-off criterion no greater than 15%, and ≤ 25% and ≤ 50% were accepted measures of
precision for fixed effect and variance parameters, respectively, a sample size of 40
subjects was sufficient. At a sample size of 40 subjects, the power to detect the covariate
effect was > 80% at a significance level of P = 0.01.
It has been widely recognized that the sample size estimation of a PopPK study is
considerably influenced by changing study design factors and model properties, such as
the allocation of blood sampling times, number of blood samplings, estimation
algorithms in NONMEM, and the magnitude of between-subject variability and residual
variability [124, 127, 139, 140]. For example, FO and FOCE methods are two commonly
used NLME estimation algorithms to obtain parameter estimations in NONMEM VI. FO
might result in considerable bias in parameter estimation due to approximation of the true
likelihood function. Compared to FO, FOCE is considered to perform better and with less
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bias in parameter estimation when there is large between-subject and residual variability.
Therefore, FOCE was selected as the only estimation algorithm throughout the simulation
study. To focus on our target question of interest, the impact of other estimation methods
in NONMEM was not investigated in the current simulation study. However, the
proposed approach also can be used to assess the performance of other NLME estimation
methods, such as first order conditional estimation with interaction (FOCEI) in
NONMEM VI, stochastic approximation expectation maximization (SAEM), Monte
Carlo importance sampling (IMP), Monte Carlo importance sampling assisted by mode a
posteriori (IMPMAP), and Markov chain Monte Carlo Bayesian (BAYES) in NONMEM
VII. The application of D-optimality-based, limited sampling schemes is well
acknowledged for increasing trial efficiency and minimizing the necessary number of
blood samples by providing informative sampling designs [141-143], which obviously is
beyond the discussion of this chapter due to our specified opportunistic sampling
characteristics. However, we can still expect a reduction in the number of patients
required for reaching the same level of success rate/”power” using an extensive blood
sampling design or optimal sampling scheme compared to the sparse and opportunistic
sampling design. The proposed approach may also prove valuable in studying other drugs
of interest in premature infants if appropriate prior knowledge is available.
Conclusions
In conclusion, we developed a full model-based simulation approach to the
sample size determination for PopPK studies in premature neonates. A mixed and
unbalanced sampling design was used in the analysis. For a desired accuracy, precision
and study power, the appropriate number of patients with a specified sampling design
was determined using the proposed approach. While the accuracy and precision of
parameter estimation were shown to benefit from increases in the number of subjects in
the evaluated observational study approach, designs with 20 premature neonates were
shown to be inadequately powered to allow for accurate and precise estimation of PopPK
parameters. Designs with > 40 subjects were required for ≤ 15% in bias, and ≤ 50% in
precision for parameter estimations of both fixed and random effects with adequate
power. This result will be useful in selecting samples sizes for upcoming clinical studies
in premature neonates.
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CHAPTER 4. POPULATION PHARMACOKINETIC ANALYSIS OF
CAFFEINE IN PREMATURE NEONATES WITH APNEA
Introduction
Apnea of prematurity (AOP)
Apnea of prematurity (AOP) is one of the major concerns in premature neonates.
AOP is defined as the cessation of breathing that lasts for 15 or 20 seconds and is usually
accompanied by dangerous hypoxia and/or bradycardia [144]. The incidence of AOP
increases with increasing prematurity of birth. It affects approximately 85% of neonates
with birth age < 34 weeks gestational age (GA), while reaching nearly 100% in infants
born at < 29 weeks GA or having birth weight < 1 kg [145]. AOP is commonly treated
with methylxanthines such as caffeine (1, 3, 7-trimethylxanthine) and theophylline (1, 3dimethylxanthine) as respiratory stimulants.
Application of caffeine in patients with apnea of prematurity
Being the current first-line pharmacotherapy for the treatment of AOP, caffeine
has been used frequently for more than three decades [99]. Caffeine therapy is believed to
reduce the number of apnoeic episodes, the duration of respiratory support of continuous
positive airway pressure (CPAP), the incidence of bronchopulmonary dysplasia (BPD)
and, from a long-term view, the morbidity of neurodevelopmental disability in very low
birth weight premature infants [144-146]. In most cases, its administration to neonates
and infants was empirical and off-label, the first and to date the only commercially
available caffeine product, CAFCIT®, was approved by the U.S. Food and Drug
Administration (FDA) at the end of the last century. This medication is labeled for the
short-term treatment of AOP in premature infants 28-33 weeks GA. Therefore, dosing
guidance remains empiric and variable for those extremely low birth weight (ELBW)
infants (birth weight < 1000 g), which are also the youngest premature neonates (23 <
GA < 28 weeks) [147]. The percentage of infants who are ELBW and very low birth
weight (< 1500 g) has steadily been increasing in the last ten years. A new cohort of
neonates, so-called fetal infants, whose birth weight is < 500 g, is also growing. This
increase might be associated with multiple reasons, such as:
•

Increased incidence of very premature birth is associated with multiple
pregnancies and multiple births caused by assisted reproductive technology
(ART);

•

Improved neonatal survival due to technological advancement in perinatal and
neonatal care; and

•

Progress in the medical management, increases in early cesarean section and
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induction of labor due to pregnancy complications or health problems.
Because of the increasing survival of ELBW infants, the burden of morbidity
from AOP and its associated BPD is growing. However, there is only a limited amount of
pharmacokinetic (PK) data for caffeine available for this newly emerging population of
premature infants. This population is susceptible to developmental changes that can affect
the disposition of drugs. Many neonatal conditions in physiology and pathology are
unique, and their pharmacokinetic characteristics have rarely been investigated. As
discussed in Chapter 1, linear extrapolation of dosing regimens based on body weight or
body surface area may not be appropriate and is frequently associated with adverse
events and lack of efficacy. To develop a sound, scientifically-based caffeine
pharmacotherapy in premature infants is therefore urgently needed for this patient
population to ensure safe and effective treatment of AOP. A preferable approach for
pharmacokinetic studies in pediatrics is the population pharmacokinetic modeling
approach [73]. The PopPK approach allows for utilizing sparse and unbalanced data
collected during routine clinical care, including therapeutic drug monitoring (TDM), from
individual patients to determine factors that may influence the drug behavior in the
human body. Therefore, using the PopPK method can help to overcome the scientific,
logistic and ethical limitations of traditional PK studies in premature neonates.
Objective
A number of clinical studies using caffeine have been performed in patients with
AOP. Caffeine is generally considered a safe and effective medication in the NICU.
However, the optimal dose is still not known. Future studies will focus on maximizing
therapeutic benefits while minimizing toxicity through a series of dose selection analyses
[101, 148]. The objectives of the current study were: (1) to develop a PopPK model of
caffeine in premature neonates, (2) to determine the typical PopPK parameters and
associated between-subject variability of caffeine, (3) to assess and identify potential
sources of variability of PK behavior for caffeine among premature neonatal patients
throughout infancy and (4) to use this PopPK model to further facilitate the development
of optimal dosing regimens through simulation—particularly, to correlate steady state
concentrations with response at different dosing regimens for various age/weight groups.
Methods
Approval
The current study received approval by the Eastern Virginia Medical School
Institutional Review Board, Norfolk, VA.
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Study design and patient population
A total of 560 caffeine concentration measurements were gathered from 88
hospitalized patients with the main diagnosis of apnea of prematurity from July 2008 to
December 2008 in the Neonatal Intensive Care Unit of Children’s Hospital of the King’s
Daughters, Norfolk, VA. All pharmacokinetic data were obtained retrospectively from
the medical records and routine therapeutic drug monitoring. The subjects included in the
PopPK analysis received repetitive intravenous (IV) and/or oral administration of
caffeine. Caffeine was given as an initial IV loading dose over 30 minutes, followed by
maintenance doses every 12 or 24 hour via 10 minutes IV infusion or orogastric
administration. Loading doses ranged from 6.5 to 9.5 mg/kg, while maintenance doses
ranged from 3.1 to 28.6 mg/kg/day. All blood PK samples were drawn before the
morning drug administration. All patients had reliable dosing and sampling collection
date and time information recorded and at least one associated measurable concentration
of caffeine. The covariates collected for each patient included birth weight (BW), body
weight (WT), GA, postnatal age (PNA), postconceptional age (PCA), gender, race and
the use of respiratory support. Demographic characteristics and relevant clinical profiles
of pharmacokinetic data were collected and precisely documented.
Assay methodology
Plasma concentrations of caffeine were determined in the clinical laboratory at
Children’s Hospital of the King’s Daughters with a homogenous spectro-photometric
method using a Syva enzyme-multiplied immunoassay technique performed on an
ARCHITECT® c8000™ analyzer by Abbott Diagnostics (Dallas, Texas). The assay range
was from 1.0 mg/L to 30.0 mg/L, while a dilution would be performed on the PK samples
with a concentration > 30.0 mg/L. The inter-assay coefficient of variation was 4.2% at a
concentration level of 11.0 mg/L.
Population pharmacokinetic analysis
Computer and software
The population pharmacokinetic analysis of caffeine was carried out by nonlinear
mixed-effects modeling using a NMQual 6.4.1 (Metrum Institute, Augusta, Maine)
installation of NONMEM version VI, Level 2.0 (ICON Development Solutions, Ellicott
City, Maryland) with a GNU Fortran 77 (g77) version 2.95. Data summary and figures
were prepared with Xpose [149], Census Version 1.0 [150], R 2.8.1 (http://www.rproject.org), or SAS 9.1.
Structure model development
The first order conditional estimation (FOCE) method within NONMEM was
used for the estimation in the PopPK analysis. A one-compartment model based on the
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available literature report was used to describe the caffeine concentration-time profile
[151-153]. The structural model to be tested was selected as a one-compartment model
with first-order absorption and first-order elimination without lag time. Since the
concentration data were collected during routine drug monitoring and consisted of trough
data, no information from the absorption phase after oral administration was available for
the evaluation of absorption rate constant (ka); therefore, a fixed value of 10 hr-1 was
employed to represent its rapid absorption suggested in the literature[152-154]. Caffeine
concentration data were log transformed prior to the PopPK analysis. Between-subject
variability on the pharmacokinetic parameters of caffeine was assumed to follow a lognormal distribution and was modeled with an exponential error model.
P = θ × (𝑒𝑒)𝜂𝜂
η ~N (0, ω2)

Where θ represents the typical value of a population pharmacokinetic parameter,
P is the true but unknown value of θ in the individual. η represents the population
parameter variability in model parameters, independently and randomly distributed with
mean zero and variance ω2. Stepwisely, between-subject variability on all PK parameters
was added or removed from the model. Residual error was initially modeled with an
additive error model on the log-transformed concentration data.
ln(C obs,ij ) = ln(C pred,ij ) + ε ij
ε ij ~N (0, σ2)
Where C obs,ij is the ith observed concentration in the jth subject, C pred,ij is the ith
model predict concentration in the jth subject and ε ij is the deviation of ln(C obs,ij ) from
ln(C pred,ij . ε ij ). ε is a normally distributed random variable with an average value of 0 and
variance of σ2.
A diagonal covariance matrix for the between-subject variability was initially
used. After the initial diagonal covariance matrix was identified for the base model, offdiagonal correlations were also tested if a scatter plot correlation matrix indicated
significant correlation between individual parameters calculated by the posterior
conditional estimation (POSTHOC) technique within NONMEM. Once the betweensubject variability covariance matrix was determined, the residual error model was also
further evaluated with a proportional and additive error model on the log-transformed
concentration data.
Initially, the basic model was evaluated without any covariates. Due to the fact
that demographic factors such as weight and age play a significant role in determining
pediatric pharmacokinetic parameter estimates and exploratory modeling results, body
weight was included a priori during the base model development, along with fixed
allometric exponents of 0.75 and 1 for clearance (CL) and volume of distribution (V),
respectively. Fixing one of the covariate-parameter relationships to an allometric
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expression allows estimation of effects of other covariates if these covariates are highly
collinear [73]. The use of these coefficients is supported by fractal geometric concepts
and observations from diverse areas in biology [39, 73].
WT

CL = θ𝐶𝐶𝐶𝐶 × (Median )0.75
WT

Covariate model development

V = θ𝑉𝑉 × (Median )1

Once the base model was identified, the influence of subject-specific covariates
on the estimated PK parameters was evaluated. The covariates screened included PNA,
GA, PCA, BW, low gestational factor (LGA), gender and race. Prior to the covariate
model development, a scatter plot correlation matrix was developed to identify any high
intercorrelation among covariates.
For continuous covariates, scatter plots of individual PK parameter estimates
against covariates overlaid with a LOESS smooth line were used to help identify
functional relationships. For categorical covariates, box and whisker plots of individual
PK parameters for each of the groups were used to identify differences between groups.
Continuous covariates were modeled using proportional or linear relationships in a
median-centered manner:
P = θ 1 + θ 2 × (COV - Median)

P = θ 1 + θ 1 × θ 2 × (COV - Median)

Where θ 1 represents the typical value of a PK parameter in an individual with the
median value for the covariate (COV) and θ 2 represents the coefficient for the
relationship with the covariate. P is the individual pharmacokinetic parameter. If the
scatter plot between the covariate and the individual PK parameter indicated a log-linear
or exponential relationship, the following power model was used:
COV

P = θ1 × (Median )θ2
COV

P = θ1 + (Median )θ2

Combinations of proportional, linear and power models were developed as
needed. Categorical covariates were modeled using a fractional change model:
P = θ 1 × (1 + θ 2 × COV)

Where COV has either the value of 0 or 1.
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The covariate model was developed using a stepwise forward addition and
backward elimination approach. First, covariates were added to the base model
incrementally in a univariate fashion and were tested to determine whether there was a
statistically significant decrease in objective function value of 3.84 (p < 0.05) based on
the Chi-square test with one degree of freedom. Covariates that demonstrated significant
PopPK model improvement were considered for the next iteration of covariate model
development. The covariate model demonstrating the greatest improvement in the PopPK
model was incorporated into the base PopPK model while remaining covariates were reevaluated incrementally. This process was repeated until none of the remaining covariates
provided significant improvement to the PopPK model.
Following determination of the fully parameterized PopPK model, a backward
elimination approach was used to evaluate if all covariates included in the full model
continued to provide significant influence on PK parameter estimations. Thus the
included covariates were sequentially removed from the full model to determine if there
was significant model deterioration. A more stringent p-value of 0.01, based on the Chisquare test with one degree of freedom, was used during the backward elimination
process to avoid false-positives. This process was repeated until the model contained the
minimum number of parameters that produced no significant PopPK model deterioration.
Covariate model development also was guided by considering physiological and
pharmacological mechanisms, reduction in the between-subject variability on the
corresponding PK parameters and improvement of goodness-of-fit plots.
Model selection
The following criteria were applied during model development to identify an
improved model:
•

A significant reduction in the objective function value based on the likelihood
ratio test. A decrease of > 3.84 points in objective function value was
considered significant (p < 0.05) for addition of one model parameter.

•

The improvement in pharmacokinetic parameter estimation, such as a decrease
in the estimated standard error for model parameters, a decrease in the
magnitude of the between-subject variability for pharmacokinetic parameters
and/or a decrease in the magnitude of the residual error.

•

Evaluation of the goodness-of-fit plots, including a less systematic or narrower
distribution of individual predicted versus observed dependent variable and a
random distribution in the residuals/weighted residuals versus the predicted
dependent variable, versus time or versus covariates.
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Population pharmacokinetic model qualification
Bootstrap analysis
A nonparametric bootstrap analysis was performed to evaluate the model
performance internally. First, 500 bootstrap data files were created from the original
NONMEM data file with repeatedly random sampling with replacement, consisting of the
same patient sample size as the original NONMEM data file. Then the population
parameters were estimated for each of the 500 bootstrap data files using the final
covariate model. The same optimization method was used in the estimation as that in the
final model. Based on these estimations, the median and 95% confidence intervals (CIs)
for each parameter were derived from the successfully converged bootstrap runs using the
percentile method and compared with the estimates of the original index dataset.
Visual predictive check
The predictive performance of the final covariate model was assessed by
conducting a visual predictive check. Using the final PopPK model with the parameter
estimates and their distributions, 500 simulations were performed with the original
dataset to preserve the covariate vector. The 90% prediction confidence intervals (5% and
95% percentiles) were determined based on the simulated plasma concentrations data.
Since actual times were used for analysis, intervals were binned around the most frequent
times after dose as determined by the data structure of the original dataset. Prediction
confidence intervals were plotted and overlaid with the observed concentrations. If
approximately 90% of the observed values judged by visual inspection laid within the
90% confidence intervals for the simulated concentrations with comparable spread, then
the PopPK model was considered to have strong predictive value.
Posterior predictive check
As a posterior predictive check, a separate Monte Carlo simulation was performed
in NONMEM with six representative subjects chosen from the model building dataset.
Dosing regimens used in this simulation were selected based on a previous dose–
optimization analysis. The results were then evaluated and compared to the observed
caffeine levels.
Shrinkage
The shrinkage for the individually estimated concentrations (epsilon shrinkage)
and parameters (eta shrinkage) were calculated [155]. Epsilon shrinkage was calculated
as 1 – SD (IWRES), where IWRES is the individual weighted residual. Eta shrinkage was
calculated as 1 – [SD (EBEs)]/ω, where EBEs stand for empirical Bayes estimates (or
individual POSTHOC parameters) and ω is the population model estimate of the SD in
eta. Although no formal criterion exists, a level of < 0.3 was used to conclude “no
relevant shrinkage.”
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Dose-optimization study
The final covariate PopPK model for caffeine (and its parameter estimates) was
subsequently applied to a dose-optimization simulation analysis. Various dosing levels
with 12 or 24 hour dosing intervals were evaluated through Monte Carlo simulations
using Trial Simulator Version 2.2 (Pharsight Corporation, Mountain View, CA).
In a meta-design, all subjects were divided into 11 sub-groups based on their body
weight and PCA. Twelve treat arms at 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12 or 14 mg/kg/day
caffeine base with dosing intervals of 12 or 24 hours given for 15 days were selected in
the evaluation based on a preliminary simulation analysis. The covariate distributions for
the simulated PCA and body weight were consistent with those in the observed caffeine
data set in terms of mean, standard deviation and range. A joint distribution between PCA
and WT for each sub-group was employed in the covariate model. Correlation
coefficients directly derived from the caffeine data set were used in the model building to
account for the slight difference in collinearity between PCA and body weight in each
sub-group. For each evaluated scenario, 400 replicates were generated. Then the peak and
trough concentrations on the 15th day for each dosing regimen were summarized and
compared to the therapeutic target concentrations of caffeine. The probabilities of
achieving the desired therapeutic target were estimated for each group.
Results
Pharmacokinetic data
The final caffeine analysis dataset consisted of a total of 560 PK samples
collected from 88 subjects with a GA of 23–31 weeks and a diagnosis of apnea of
prematurity. The dosing and baseline demographics of the subjects are summarized in
Table 4-1. The duration of caffeine treatment ranged from 9 to 107 days, with a median
of 48 days. The median number of concentration measurement provided is 6 per subject.
The majority of patients (70 out of 88 subjects) contributed 4-10 PK observations, while
13 subjects had 1-3 PK observations and 5 subjects had 11-17 PK observations. It should
be noted that only 3 subjects had a single PK observation (Figure 4-1).
Structural model
One-compartment models with very fast first-order (ka = 10 h-1) absorption, and
first-order elimination were tested using the subroutines ADVAN2 and TRANS2 within
NONMEM. Various combinations of between-subject variability (exponential) on CL, V
and F1 with or without off-diagonal correlation were explored. The residual error term
was initially modeled as an additive error on the log-transformed concentrations. The
proportional and additive residual error model was also tested once the between-subject
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Table 4-1.

Subject dosing and baseline demographics summary

Characteristics

N

Gender (male/female)
Race (Caucasian/Black/Other)
Caffeine dose (mg/kg/day)
Duration of caffeine therapy (day)
Caffeine concentration (mg/L)
Concentration measurements per patient
PNA (day)
GA (week)
PCA (week)
BW (kg)
WT (kg)

Median

Range

7.7
48
24.4*
6
39
26
32
0.84
1.3

3.1-28.6
9-107
7.9-42.7
1-17
1.0-116
23-31
24-42
0.38-1.7
0.36-3.0

38/50
28/50/10

560
88
88
88
88
88

N = number of subjects.
* Presented as mean.
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Figure 4-1. Histogram of frequences of number of caffeine concentrations
contributed per subject
Red vertical line indicates the median of the number of PK samples.
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variability had been selected. The structural base model was finally determined as a one
compartment model with no lag-time, first-order absorption, first-order elimination and
between-subject variability expressed as exponential terms on CL, V and oral
bioavailability (F1). Residual error was modeled as an additive error on the logtransformed concentrations. The models were evaluated based upon the objective
function value, goodness-of-fit plots, parameter estimates, precision of parameter
estimates, between-subject variability and residual error.
Size and maturation-related covariates (GA, PNA and PCA) are usually two
important aspects associated with pediatric analysis, and collinearity is commonly
observed (Figure 4-2). In neonatal studies, both covariates have profound but
indistinguishable impact on parameter estimation. The incorporation of allometric size
adjustment by weight centered by the median value of 1.5 kg for both CL and V was
evaluated by two approaches, a priori inclusion with fixed exponents to 0.75 for CL, 1
for V and estimation as part of the covariate model building. Both approaches gave
significant reductions (P < 0.001) of the objective function value, 438.5 and 558.8,
respectively. The allometric exponential estimates and subsequent parameter estimate of
PCA effect on CL are listed in Table 4-2.
The pros and cons of these two approaches for size adjustments in PopPK
analyses have been well discussed in the literature, particularly in a situation where
collinearity exists among the studied covariates [39, 73, 156]. To allow for the evaluation
of the influence of other covariates that are collinear with WT on the PK parameters of
caffeine, the allometric size adjustment by a priori fixing the exponents to 0.75 for
weight on CL and 1 for weight on V was finally decided on for use in the base model.
The PK parameter estimates of caffeine obtained from the base model are given in
Table 4-3.
Covariate model
Continuous covariates, including PNA, PCA, GA and BW, were tested in a linear
manner or a power function normalized with the median value on CL, V and F1.
Categorical covariates including gender and race were tested on CL, V and F1 in a
fractional change manner.
In the first forward addition step, PCA on CL (power function), low gestational
age (LGA) factor on CL, and LGA on V were found to affect the model fit significantly.
PCA on CL showed the greatest reduction (-160.4) in objective function value compared
to the base model and was then chosen as the reference model for Step 2. Various LGA
factors (when GA = 24, 25, 26, 28, 30 weeks) were evaluated, but only LGA < 25 weeks
was found to have a significant effect on both CL and V.
In the second forward addition step, only those covariates that were found
significant in the first step were tested. LGA on CL and LGA on V were significant.
Among them, LGA on CL produced the greatest decrease in objective function value
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Figure 4-2.

Matrix of continuous covariates and PK parameters of the base model
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Table 4-2.
Population pharmacokinetic parameters of caffeine obtained from the allometric model with estimated or fixed
exponentials

Model Parameters
Clearance (CL, L/hr)
Weight on CL (power)
PCA on CL
Volume of distribution (V, L)
Weight on V (power)
Absolute bioavailability (F1)

Pre-base Modela

Pre-base Modela +
PCA on CL

Base Modelb

Base Modelb +
PCA on CL

0.0169 (15.3%)

0.0164 (10.4%)

0.0144 (14.9%)

0.0166 (10.3%)

0.75

0.75

1.88

-

1.91 (0.17)c

1.19 (52.7%)

0.981 (52.6%)

1.01 (45.8%)

c

d

1.2 (0.057)

0.736

d

1.15 (56.5%)
c

d

1.45 (0.218)

1.36

1

1

0.97 (13.1%)

1.01 (13.5%)

0.824 (14.8%)

1.02 (13.9%)

Parameter estimates are presented as mean (between-subject variability, %).
a
Exponential of WT on CL and V were estimated.
b
Exponential of WT on CL and V were fixed.
c
Presented as mean (standard error).
d
Standard error not available.

73

Table 4-3.
base model

Population pharmacokinetic parameters of caffeine obtained from the

Model Parameters

Parameter Estimate

RSEa

BSVb (CV%c)

Clearance (CL, L/hr)

0.0144

2.22%

14.9%

0.75

NA

NA

0.981

7.57%

52.6%

1

NA

NA

Absolute bioavailability (F1)

0.824

2.99%

14.8%

Residual error

0.0421

8.53%

20.5%

Weight on CL (power)
Volume of distribution (V, L)
Weight on V (power)

a

Relative standard error (RSE), calculated as (Standard Error/Estimate)*100 from
NONMEM® results.
b
Between-subject variability (BSV).
c
Coefficient of variation (CV%), calculated as√𝜔𝜔 2 ∗ 100, where ω2 is the betweensubject variance estimate.
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(∆OFV = -14.3).
In the third step, only those covariates that were found significant in the second
step were tested. In the third forward addition step, LGA on V was found significant
(∆OFV = -5.13). Thus this model was then considered the fully parameterized model; it
consisted of the statistically significant relationships of a body weight effect on CL
(positive power relationship), a PCA effect on CL (positive power relationship), a low
GA effect on CL (positive fractional change), a body weight effect on V (linear
relationship) and a low GA factor on V (positive fractional change).
Removal of each of these covariates led to a significant deterioration of the
model, as indicated by an increase of more than 6.64 points in the OFV compared to the
full model. Therefore, each relationship was considered significant. The final model was
a one-compartment model with no lag-time, between-subject variability expressed as
exponential terms on CL, V and F1, and having the exponential residual error model and
covariate effects listed in the previous paragraph.
Additionally, low birth weight factor (LBW) (BW = 0.6, 0.8, 0.9, 1.0, 1.2 kg) and
respiratory support (5 rank levels of oxygen support) were also tested as potential
covariates but did not appear to be significant. The only covariates found to significantly
(p < 0.01) affect the PK parameters beyond body weight were PCA on CL and a factor <
25 weeks of gestational age at birth (LGA) on CL and V.
The final models for clearance and volume of distribution are as follows:
𝑃𝑃𝑃𝑃𝑃𝑃 1.96

𝑊𝑊𝑊𝑊

CL (L/hr) = 0.0164 ∗ ( 1.5 )0.75 ∗ � 32 �
𝑊𝑊𝑊𝑊

(∗ 1.18, 𝑖𝑖𝑖𝑖 𝐺𝐺𝐺𝐺 < 25 𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤)

Vd (L) = 0.94 ∗ ( 1.5 )1.0 (∗ 1.57, 𝑖𝑖𝑖𝑖 𝐺𝐺𝐺𝐺 < 25 𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤)
𝐹𝐹 = 1.0

The typical patient in the studied premature neonate population, i.e., a patient with
WT of 1.5 kg, PCA of 32 weeks, and GA > 25 weeks, was estimated to have a CL of
0.0164 L/hr and a V of 0.94 L. That is equivalent to 0.0109 L/kg/hr and 0.63 L/kg for CL
and V, respectively. The population typical value for absolute bioavailability was
estimated to be close to 1.
The PK parameter estimates of caffeine obtained from the final model are given
in Table 4-4. Selected goodness-of-fit plots are presented in Figure 4-3, Figure 4-4,
Figure 4-5, Figure 4-6, and Figure 4-7.
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Table 4-4.
final model

Population pharmacokinetic parameters of caffeine obtained from the

Model Parameters

Parameter Estimate

RSEa

BSVb (CV%c)

Clearance (CL, L/hr)

0.0164

2.29%

8.9%

Weight on CL (power)

0.75

NA

NA

PCA on CL (power)

1.96

8.72%

NA

Low GA on CL (fraction)

1.18

3.46%

NA

0.94

7.51%

42.3%

1

NA

NA

Low GA on V (fraction)

1.57

16.2%

NA

Absolute bioavailability (F1)

1.0

3.31%

14.2%

0.0318

8.84%

17.8%

Volume of distribution (V, L)
Weight on V (power)

Residual error
a

Relative standard error (RSE), calculated as (Standard Error/Estimate)*100 from
NONMEM® results.
b
Between-subject variability (BSV).
c
Coefficient of variation (%CV), calculated as√𝜔𝜔 2 ∗ 100, where ω2 is the betweensubject variance estimate.
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(a)

Figure 4-3.
final model

(b)

(c)

Goodness-of-fit plots for the structural model, the base model and the

Population (upper panel) and individual (lower panel) predicted versus observed caffeine
concentrations obtained from the structural model (a), base model (b), and final model
(c).
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Figure 4-4. Conditional weighted residuals versus population predicted
concentrations, observed concentrations, time after dose and subject ID in the final
covariate model
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Figure 4-5. POSTHOC individual estimates of clearance and its variance term
(ETA1) obtained from the final model versus covariates
Upper panel: scatter plots of POSTHOC individual estimates of clearance versus
covariates including body weight, postconceptional age, and gestational age. Lower
panel: scatter plots of variance term for clearance (ETA1) versus covariates, including
body weight, postconceptional age and gestational age, obtained from the final model.
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Figure 4-6. POSTHOC individual estimates of volume of distribution and
variance term (ETA2) obtained from the final model versus covariates
Upper panel: scatter plots of POSTHOC individual estimates of volume of distribution
versus covariates, including body weight and gestational age. Lower panel: scatter plots
of variance term for volume of distribution (ETA2) obtained from the final model versus
covariates including body weight and gestational age.
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Figure 4-7.
patients

Caffeine plasma concentration-time profiles in selected sixteen

Patient ID as indicated. Plots of population predicted, individual predicted and observed
concentrations versus time. Measured plasma concentrations versus time are indicated by
open circles; model-based population and individual predicted concentration-time
profiles by dashed and solid lines, respectively.
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Model diagnostics
Nonparametric bootstrap
Results from the bootstrap analysis of 500 datasets indicated a stable final model.
100% bootstrap runs attained successful minimization. Table 4-5 shows that the
difference in parameter estimates between the original NONMEM input dataset and the
bootstrapped datasets were generally less than 5%, indicating good stability of the final
model. Only the estimation of BSV on V (�(𝜔𝜔2 ) x100%) from the bootstrap was 11.5%
lower than that from the final model; however, its 95% CI was narrower and completely
covered by the 95% CI of the same estimate in the final model. The 95% confidence
intervals for the covariate effects did not overlap with 0, indicating the statistical
significance of the covariates included in the final model. The 95% confidence intervals
were relatively tight, also indicating good precision of all parameter estimates.
Model predictability
Visual predictive check plots were constructed to evaluate the model
predictability. Figure 4-8 shows the observed caffeine concentrations, together with the
median and predicted 90% CIs from 500 simulation data sets based on the final model.
The visual predictive check confirmed that a majority of the observed values were within
the 90% CI of the simulated concentrations by time with similar spread. Therefore, the
final full model is considered to be predictive for the model development dataset.
Shrinkage
ETA shrinkage and epsilon shrinkage were calculated for the base model and final model.
The shrinkage evaluation results are presented in Table 4-6. As mentioned earlier in this
section, the dataset used in the PopPK analysis included 88 patients who contributed 1-17
PK observations. While the majority of patients contributed 4-17 PK observations, 13
patients had only 1-3 PK observations. When data are uninformative, the variance for the
distribution of individual parameter estimates will shrink towards zero and eta shrinkage
will be close to one. Meanwhile, individual predicted concentrations will shrink towards
the corresponding observed concentrations and individual weighted residual will thus
shrink towards zero, resulting in a high epsilon shrinkage [157]. As expected, some
shrinkage was observed for eta and epsilon, which is consistent with the sparse data used
in the current analysis. While the value of using individual estimates in the diagnostic
plots is considered to decrease in the case of significant shrinkage (eta and epsilon), the
population parameter estimation is not affected. Additionally, less reliance on the
individual estimate-based diagnostics should be applied in the model building process
when a significant shrinkage is observed for eta and epsilon [157]. In this analysis, model
selection did not solely rely on the diagnostic plots using individual estimates; instead,
multiple model selection criteria were used to determine the best model, as mentioned
earlier in the methods section. Meanwhile, other types of diagnostics, including
conditional weighted residuals and simulation-based diagnostics, were used to facilitate
the selection of an improved model. Thus, the effects of moderate eta and epsilon
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Table 4-5.
Comparison of parameter estimates after modeling the model building dataset and the 500 bootstrap derived
datasets for the final model
Model Parameters
Clearance (CL, L/hr)
BSV on CL (%CV)

0.0164

Bootstrap
Parameter
95% CI
Estimate

Difference
in Estimatea
(%)

(0.0157, 0.0171)

0.0164

(0.0157, 0.0171)

0.0%

0.00793 (8.9%) (0.00364,0.0122)

0.00755

(0.00341, 0.0127)

- 4.8%

Weight on CL (power)

0.750

NA

NA

NA

NA

PCA on CL (power)

1.96

(1.62, 2.30)

1.97

(1.64, 2.33)

0.5%

Low GA on CL (fraction)

1.18

(1.10, 1.26)

1.17

(1.09, 1.25)

-0.8%

0.940

(0.802, 1.08)

0.926

(0.775, 1.07)

-1.5%

0.179 (42.3%)

(0.0394, 0.319)

0.1585

(0.000305, 0.288)

-11.5%

1

NA

NA

NA

NA

Low GA on V (fraction)

1.57

(1.07, 2.07)

1.59

(1.16, 2.29)

1.3%

Absolute bioavailability (F1)

1.00

(0.963, 1.10)

1.03

(0.970, 1.10)

3.0%

0.0199

(0.00879, 0.0345)

0.0314

(0.0262, 0.0373)

Volume of distribution (V, L)
BSV on V (%CV)
Weight on V (power)

BSA on F1 (%CV)
Residual error
a

Final Model
Parameter
95% CI
Estimate

0.0201 (14.2%) (0.00732,0.0329)
0.0318

(0.0263, 0.0373)

Calculated as (bootstrap value – final model value) / final model value *100.
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-1.3%

Figure 4-8. Visual predictive check for the final caffeine population
pharmacokinetic model.
The red solid line and grey dotted lines indicate the median and 90% confidence interval
of predicted concentrations determined from 500 Monte Carlo simulations with the final
model. Open circles indicate observed caffeine concentrations in the model building
dataset.
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Table 4-6.

Shrinkage evaluation for the base and final model

Parameter

Base Model Shrinkage

Final Model Shrinkage

ETA1 (CL)
ETA2 (V)
ETA3 (F1)
Epsilon

0.209
0.367
0.417
0.776

0.324
0.338
0.356
0.778

shrinkage on the modeling results are considered to be limited.
Dose-optimization study
A description of the trial simulation cohorts is summarized in Table 4-7. The
simulated subjects in each cohort had the same demographic characteristics as the infants
in the model building dataset of the caffeine PopPK analysis, except for one hypothetical
subgroup. Infants with a body weight > 2 kg and a PCA >28 but ≤ 32 weeks were not
available in the model building dataset but were considered clinically relevant. Therefore
this group was also included in the simulation study. Consistent with the original caffeine
dataset, covariate models were defined with a range of 24 to 42 weeks for PCA [mean =
32 (± 3) weeks] and a range of 0.36 to 3 kg for body weight [mean = 1.3 (± 0.45) kg]. A
joint distribution between PCA and WT for each studied subpopulation group was
derived from the model building dataset for the caffeine population analysis and modeled
with a correlation coefficient of 0.36 (range: 0.209 - 0.407). Subjects following the above
covariate distribution were generated by using the Trial Simulator. The simulation was
stratified so that 20% of the simulated patients had GA < 25 weeks, while 80% simulated
patients had GA ≥ 25 weeks.
Model-based simulation was used to evaluate various candidate dosing regimens
with regard to a desired therapeutic target concentration. However, there is currently no
consensus on the desired caffeine target range in the pediatric community, and thus
targets may vary from hospital to hospital and physician to physician. Based on a
literature review and the CAFCIT® package insert, the therapeutic targets to attain the
satisfactory efficacy and minimize toxicity were defined for the current analysis as: (1)
maintaining a trough caffeine concentration at steady state between 8 and 20 mg/L; and
(2) maintaining a peak concentration ≤40 mg/L, since caffeine concentrations > 50 mg/L
are considered to cause critical toxicity [113, 158]. Maintenance dose recommendations
used for posterior check were derived from the frequencies with which the therapeutic
targets were achieved in 400 simulated patients for each cohort. Figure 4-9 illustrates the
simulated caffeine peak and trough concentrations sorted by PCA-body weight group and
daily dose.
Based on the simulated dose escalation study results using Trial Simulator, the
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Table 4-7.

Description of the simulated cohorts
PCA
(week)

Weight
(kg)

LGA a
(%)

Dose b
(mg/kg)

Interval
(hour)

Duration
(day)

Sample
Size

PK Target c

23 < PCA ≤ 28

0.36 < WT ≤ 1
1 < WT ≤ 2

20

2-12

12 or 24

15

400

C SS,trough 8-20 mg/L
C SS,peak ≤ 40 mg/L

28 < PCA ≤ 32

0.36 < WT ≤ 1
1 < WT ≤ 2
2 < WT ≤ 3

20

2-12

12 or 24

15

400

C SS,trough 8-20 mg/L
C SS,trough ≤ 40 mg/L

32 < PCA ≤ 36

0.36 < WT ≤ 1
1 < WT ≤ 2
2 < WT ≤ 3

20

2-14

12 or 24

15

400

C SS,trough 8-20 mg/L
C SS,peak ≤ 40 mg/L

36 < PCA ≤ 42

0.36 < WT ≤ 1
1 < WT ≤ 2
2 < WT ≤ 3

20

2-14

12 or 24

15

400

C SS,trough 8-20 mg/L
C SS,peak ≤ 40 mg/L

a

LGA (%): percent of subjects with low gestational age (< 25 weeks) at birth.
Dose (mg/kg): caffeine base.
c
Steady state is reached after 15 days of caffeine treatment when half-life is less than or equal to 70 hours. C SS,trough and C SS,peak
represent the simulated trough and peak concentrations on the day 16.
b
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Figure 4-9.

Trough and peak levels of caffeine concentrations at the steady state in dose-finding simulation study

Red solid lines indicate the predetermined therapeutic target range for trough concentration of caffeine: 8-20 mg/L.
Blue dash lines indicate the predetermined therapeutic target for peak concentration of caffeine: 40 mg/L.
Orange dash lines indicate the toxicity level of caffeine: 50 mg/L.
Green box plots indicate maintenance dose level of caffeine base 2.5mg/kg QD, which is equivalent to 5 mg/kg CAFCIT® (caffeine
citrate) approved by the FDA for short-term treatment in premature infants with 28-33 weeks GA.
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Figure 4-9.

Continued
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Figure 4-9.

Continued
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Figure 4-9.

Continued
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Figure 4-9.

Continued
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probability of achieving the therapeutic target was calculated for each group and the
results are summarized in Table 4-8. As illustrated in this table, a higher dose per body
weight appeared to be needed to reach the predetermined target concentrations with a
decrease of body weight when PCA was > 23 weeks but ≤ 28 weeks. Similar trends were
also observed for other three study groups. This was in agreement with the fact that low
body weight is usually correlated with low gestational age, and thus may lead to a
relatively high clearance per kg body weight for caffeine. Meanwhile, a higher dose per
body weight is generally needed with an increase in PCA within the same range of body
weight as shown in this figure. Maintenance dose recommendations were derived based
on the criterion that the predetermined target range in the simulated premature infants
was achieved with a frequency > 99.5%. Table 4-9 shows that the selected maintenance
doses for specific age and body weight groups were consistent with trends as observed in
Table 4-8. While both 12-hour and 24-hour dosing intervals were evaluated in the dosefinding simulation analysis, dosing every 24 hours can reach the predetermined target and
it was selected, since it is more convenient for patient care than a twice daily dosing
regimen.
On the basis of the dose-finding simulation results, plasma PK profiles of caffeine
in six representative patients after 15 days of dosing were then simulated (n = 500
replicates) under the suggested dosing regimens (Table 4-9) using NONMEM. The
patients were selected so their covariates covered the range of all studied scenarios in
Table 4-8, except for the hypothetical group – body weights ≥ 2 kg with a PCA between
28 and 32 weeks, which were not available in the clinical dataset. Simulations were
performed using the final PopPK model considering individual parameter estimates,
between-subject variability and residual variability. The median predicted concentrationtime profiles and 90% CIs from 500 replicates were generated for each patient and
compared, with the observed concentrations from the patients included in the Model
Building Dataset, who received an empirical and adaptive dosing of caffeine at 5.111.7 mg/kg/day, administered every 12 or 24 hours. As presented in Figure 4-10, the
estimated caffeine concentrations under the new suggested dosage regimen were lower
than the observed values. The differences in caffeine concentrations were likely caused
by the different therapeutic target concentrations. As discussed earlier, the therapeutic
target in the current dose-optimization simulation analysis was a trough caffeine
concentration between 8 and 20 mg/L and a steady state peak concentration ≤ 40 mg/L.
However, the target trough concentrations for the patients included in the Model Building
Dataset were much higher (20-30 mg/L) than the targets used in the current simulation
analysis. With the proposed dosing regimens, the predetermined target was well attained,
and the simulated median trough plasma concentrations were between 8 and 20 mg/L
throughout the treatment period.
The caffeine population pharmacokinetic model
In the present study, we developed a PopPK model that describes the
pharmacokinetic characteristics of caffeine in premature infants, covering a GA of 23 to
31 weeks with a PNA of up to 116 days. Body weight, PCA and a low gestational age
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Table 4-8.

Frequency of Css fall in therapeutic target at the different dose levels of caffeine base

PCA (week)
23 < PCA <= 28

28 < PCA <= 32

32 < PCA <= 36

36 < PCA <= 42

Weight (kg)

Dose (mg/kg/day)
2

2.5

3

4

5

6

7

8

9

10

12

14

WT <= 1

24.5

82.5

99.25

99.75

87.25

29.25

1.75

0

0

0

0

NA

1 < WT <= 2

74.25

100

100

88.75

20.25

0.25

0

0

0

0

0

NA

WT <= 1

0

9.25

55

99

100

97

70.5

30.25

9.75

0.25

0

NA

1 < WT <= 2

6

65.25

98.75

100

93.75

50.75

7.75

0

0

0

0

NA

WT > 2

32.5

97

100

100

64.5

9

0

0

0

0

0

NA

WT <= 1

0

0

NA

65.5

96.5

100

100

94.75

73.5

38.75

4.25

0.25

1 < WT <= 2

0

2.25

NA

99.5

100

100

78.5

34.75

4.75

1.25

0

0

WT > 2

0

32

NA

100

100

82

24.25

2.25

0

0

0

0

WT <= 1

0

0

NA

0

54

92.25

99

100

100

100

57.75

6.25

1 < WT <= 2

0

0

NA

63.75

98.25

99.75

100

100

78.75

38.25

3.5

0.25

WT > 2

0

0

NA

94

100

100

100

67

22

4.25

0.25

0

PCA = postconceptional age; WT = weight; NA = not applicable.
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Table 4-9.
Suggested intravenous maintenance dose (mg/kg/day QD) for caffeine
base in premature infants stratified by PCA and body weight
Body Weight (Kg)

PCA
(week)

<=1

(1,2]

>2

< = 28
(28, 32]
(32,36]
> 36

4
5
6
8

3
4
5
6

3
4
5
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Figure 4-10. Simulated caffeine concentration-time profiles in 6 representative
patients using the dosing regimens suggested in Table 4-9.
Observed caffeine plasma concentrations after adaptive dosing are indicated by open
circles; blue and gray solid lines represent the median and 90% confidence intervals
generated from 500 Monte Carlo simulations.
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< 25 weeks were found to be important predictors explaining the between-subject
variability of caffeine pharmacokinetics in premature infants receiving caffeine treatment.
Overall, the BSV of CL decreased from 28.0% to 8.9% with the addition of body weight,
PCA and low GA factor on CL. Particularly, inclusion of body weight, PCA and low GA
factor reduced the between-subject variability in CL from 28.0% to 14.9%, from 14.9%
to 10.3%, and from 10.3% to 8.9%, respectively. The median (range) empirical Bayesian
estimates of parameters for all individuals were 11.6 (7.1-20.3) mL/hr/kg for clearance
and 0.67 (0.39-2.28) L/kg for volume of distribution. These results are in agreement with
those reported in the literature involving premature infants receiving caffeine treatment
(Table 4-10).
An allometric model with fixed exponents of 0.75 and 1 was used to model the
effect of body weight on clearance and volume of distribution. The allometric principle
has a concrete ecological rationale based on fractal geometry theory and is robust when
used as size adjustment in pharmacokinetics [39, 159]. This rationale allowed us to
explore the unique effect of other covariates, despite their collinearity with body weight
[73]. Body weight explained 46.8% of the reduction in BSV for CL. PCA was
subsequently found to be another significant covariate of caffeine’s CL, and clearance
increased nonlinearly with PCA. The addition of PCA on CL explains 30.7% of the
reduction in BSV for CL. Both PCA and PNA were determined to be significant
predictors for CL when tested stepwise in the base model during the model building
procedure. The addition of PCA on CL demonstrated a better improvement in the model
fit and explained more of the BSV of CL than PNA did. After the addition of PCA on
CL, PNA did not improve the model fit further and resulted in over parameterization.
This result is also in accordance with our hypothesis prior to the covariate screening.
Compared to PNA, PCA is considered more physiologically appropriate [160], especially
when maturational processes of CL are initiated before birth and/or the study population
is heterogeneous with respect to GA and PNA at the onset of the pharmacotherapeutic
intervention. In this case, PCA was expected to contribute more relevant information with
regard to maturation of drug disposition processes rather than PNA or GA alone.
A sigmoid maturation model was also investigated to describe the age effect on
clearance maturation since the maturation process of CYP1A2 could be modeled by this
Hill type function [161], as seen in the following equation:
Maturation Function =

(𝐴𝐴)𝑛𝑛

𝐴𝐴 50 𝑛𝑛 +(𝐴𝐴)𝑛𝑛

Where A represents the age term, such as PCA or PNA; A 50 is the age term at
which clearance is 50% that of the mature value and n is the Hill coefficient. Both PCA
and PNA were tested but did not result in a successful model fit. There are several
reasons that might account for this failure. First, this model might better describe those
maturational progresses triggered by parturition [39]. However, the maturation of
processes relevant for caffeine’s clearance may start already before birth. Secondly, there
is no clear information available for the ontogeny of clearance mechanism in the studied
population. The elimination of caffeine in neonates is not dominated by one pathway,
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Table 4-10.
literature

Comparison of pharmacokinetic parameters of caffeine in premature infants in our study and as reported in the

Reference

N

CL
(mL/h/kg)

V
(L/kg)

T 1/2

(h)

Birth Weight
(kg)

GA
(week)

PNA
(day)

PCA
(week)

Weight
(kg)

Current study

88

11.6
(7.1-20.3)

0.67
(0.39-2.28)

40.0
(16.8-162.1)

0.84
(0.38-1.7)

26
(23-31)

39
(1-116)

32
(24-42)

1.3
(0.36-3.0)

Aranda
et al. [153]

12

8.9
(2.5-16.8)

0.92
(0.48-1.28)

102.9
(40.8-231)

1.11
(0.69-1.87)

28.5
(25-34)

11.5
(3-32)

Gorodischer
et al. [162]

13

8.5
(5.8-12.2)

0.78
(0.47-1.01)

65
(48.2-87.5)

1.4
(0.92-2.06)

30.6
(25-34)

1-42

Le Guennec
et al. [160]

23

1.42
(0.64-2.35)

30
(25-36)

Thomson
et al. [163]

60

7.9

0.82

23
(1-100)

31
(25-41)

1.3
(0.6-2.9)

Falcão
et al. [151]

75

7.6

0.91

0.6-2.0

23-35

1-78

26-38

0.6-2.7

Lee T.C.
et al. [164]

89

4.4-5.6

0.86-1.11

1.17
(0.57-2.31)

28.2
(24-31)

Micallef
et al. [165]

35

1.34
(0.66-2.17)

29.1
(23-32)

Saleh Al-Alaiyan
et al. [166]

80

7.62
(2.8-30.2)

NA

1.3
(0.65-2.26)

30
(24-34)

28
(5-60)

34
(29-40)

1.63
(0.98-2.67)

Lee H.S.
et al. [167]

18

6.28 *
(17.5%)

0.96 **
(20.3%)

1.12
(0.68-1.7)

28.9
(24-33)

NA

NA

NA

Charles
et al. [152]

110

6.96
(1.61-22.6)

0.85
(0.37-1.76)

1
(0.568-1.57)

27.6
(24-29)

12
(1-45)

29
(24-34)

0.99
(0.66-1.86)

NA

101
(24.5-371)
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Table 4-10.

Continued

* unit (L/h) ** unit (L)
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instead, complementary pathways keep changing as the maturation of kidney and liver
proceed, resulting in a complex effect on the overall CL. Thirdly, variation of other
factors relevant for the disposition of caffeine, such as low albumin levels (binding
protein), body composition or bilirubinemia may confound estimations of hepatic
clearance [168, 169]. Another possible reason might be the limited data in this study:
They are not rich enough to support estimating parameters in this sigmoid maturation
model and age (PCA, PNA) span in the analysis dataset is too narrow to characterize this
maturation function appropriately.
Study results compared to the literature
Compared to the published literature, our study presents substantial new findings
in those extremely premature infants with GA < 25 weeks. A patient with GA < 25 weeks
at birth has 18% higher allometrically weight adjusted CL and 57% higher weight
adjusted V compared to one with GA > 25 weeks. These findings suggest that a relatively
higher loading dose and higher maintenance dose based on body weight would benefit in
treating AOP in premature infants with a GA < 25 weeks at birth. The relatively larger
estimate for V is also consistent with estimates previously reported, where body weight
normalized V for caffeine in premature neonates is larger than that in term neonates and
adults [101, 170]. Similar dose guidance was suggested by a controlled trial of caffeine
citrate [101], when Erenberg et al. proposed a larger loading dose for less mature infants
[101]. It is probably because there is proportionally more extracellular fluid in less
mature infants, which leads to an age-dependent larger water/body weight ratio [171].
Caffeine, as a highly hydrophilic drug, would be expected to demonstrate an increased
apparent volume of distribution under these conditions [26, 48]. It should be noted that a
relatively large BSV (42.3%) on V was observed in the current study. This is likely due
to the fact that most concentration data were collected at trough level during the TDM.
Little information is available for the estimation of the absorption phase and peak
concentrations, thus affecting the estimation for V. Another reason might be that water
loss could be easily induced in premature neonates by environmental factors or clinical
treatment, such as phototherapy, using a radiant warmer, or diuresis after caffeine
treatment. As a result, a large between-subject variability and within-subject variability
for V is often observed in this patient population.
The inclusion of a low GA factor in the CL model indicates that size and PCA
alone cannot explain well the maturation progress of caffeine CL in extremely premature
infants. PNA might play an important role in this process as well, where the postnatal
development trajectory does not follow the intrauterine curve during the early postnatal
life. A literature review also showed that most previous caffeine studies had detected a
correlation between caffeine CL and PNA [152, 163, 166], PCA [160] or the combination
of GA and PNA/PCA [151, 164]. In the studies by Falcão [151] and Lee [164], a
corrected factor of GA ≤ 28 weeks was incorporated in the CL model, which found that
PNA and weight had influence on CL. It has been reported by Pons et al [172] that the
development of caffeine clearance after birth reached the plateau after 4-6 months, while
a linear relationship was observed with gestational age and an exponential relationship
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with postnatal age based on a study with a PNA range of 15~588 days. These findings are
in agreement with our conclusion that together with size as a covariate, neither PNA nor
PCA can solely characterize the maturation process of caffeine disposition in premature
infants. That process might be described better by the combination of two types of age
covariates, as implemented in our population model. In this way, the variable degree of
maturation at birth and postnatal development are both accounted for in the CL model.
This approach is also supported by a fluconazole population study in neonates and
infants, where both GA and PNA were included in the CL model for fluconazole [173].
The ontogeny of caffeine elimination
Understanding the impact of the ontogeny of various elimination pathways on
caffeine CL in premature infants remains incomplete. The total clearance of caffeine in
premature neonates cannot be compared to term neonates and adults due to the immature
liver and kidney functions at birth. In adults, caffeine is predominantly metabolized
through cytochrome P450 (CYP) enzymes in the liver, and only approximately 2% of
caffeine is excreted unchanged in urine [154, 174]. Of the human CYP enzymes
investigated, demethylation through CYP1A2 plays the most important role [175-178].
Besides, CYP2E1, CYP3A4, N-acetyltransferase (NAT) and xanthine oxidase (XO) are
all associated with caffeine’s biotransformation as well [166, 177, 179, 180].
In contrast to the adult situation, the renal pathway is thought to be compensatory
in newborns and remains dominant for at least 3 months after birth. As indicated by a
lack of expression of mRNA in human fetal liver, there is no significant enzymatic
activity of CYP1A2 at birth [181]. Development is believed to be triggered by parturition
[166, 181]. Previous studies support these mechanistic considerations by reporting that
renal clearance plays an important role on caffeine’s elimination in neonates.
Transplacentally acquired caffeine was found to be almost completely recovered in urine
during the first 3 days after birth [182]. Additionally, 85% of the ingested dose was
excreted unchanged in the urine during the first month of life [174]. However, renal
clearance is less efficient than the CYP1A2-mediated metabolism pathway. Thus, the
magnitude of the reduction of overall caffeine clearance in neonates could be as large as
10-fold [170]. Adult clearance levels are reached in 4 to 6 months after birth [48, 130,
160, 183], which reflects largely the metabolic activity of CYP1A2.
Nephrogenesis starts as early as 9 gestational weeks. Neonatal glomerular
function shows a progression positively correlated to GA and PNA [31, 184, 185]. There
are data to show that renal creatinine clearance (CrCL) was significantly lower in the low
GA population (GA < 30 week), and steadily increased after birth [184, 186]. These
findings about the development of renal elimination in neonates support the selection of
GA and PCA as predictors for caffeine CL. Additionally, a considerably decreased
glomerular filtration rate (GFR) was detected in neonates with perinatal asphyxia [187].
Although creatinine values were significantly higher in preterm babies than in term
babies in the first week, they reached almost similar levels by the third week of life [188].
Such data indicate that a relatively faster development of renal function might be
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associated with less mature neonates during the first 3 weeks of life, and thus may
explain the effect of a low GA on caffeine CL. However, further studies are needed to
clearly define the underlying mechanism of the development of caffeine elimination
pathways.
Dosing recommendations
An essential goal of the current dose-optimization simulation study was to find
appropriate dosing regimens that can reach a trough level of 8-20 mg/L and a peak level
≤ 40 mg/L for caffeine at steady state for the treatment of AOP in premature infants.
Using trial simulation, four clinically relevant age categories were investigated using
doses from 2 mg/kg to 14 mg/kg with a 12-hour or 24-hour dosing interval. Although
patients received maintenance doses ranging from 3.1 to 28.6 mg/kg/day with either 12 or
24 hours of dosing interval in the Model Building Dataset, a 24-hour-dosing interval was
shown to be successful by the Monte Carlo simulations in the present study with respect
to the proposed target concentrations in all simulated groups. This finding is also
supported by the remarkably prolonged half-life of caffeine as reported previously in this
population [153, 160]. However, a trend was noted that peak-trough fluctuation at steady
state appeared to increase with the increase of patients’ body size and age.
Moreover, a large variability on the clinical responses of caffeine was observed in
the original Model Building Dataset, where an empirical and adaptive dosing was used
with the target trough concentrations between 20 and 30 mg/L. For example, 13 out of 88
patients still had uncontrolled apnea and bradycardia episodes (1-26 episodes/patient)
following at least 10 days of caffeine treatment. Meanwhile, 50 out of 88 patients had
tachycardia (heart rate > 180 bpm) during the caffeine treatment period, where caffeine
trough concentrations ranged from 7.9 to 42.7 mg/L. This variability is likely due in part
to limitations of the empirical dosing strategy, where the therapeutic target is adjusted
individually through TDM to achieve an effective clinical effect. However, the doseoptimization simulations based on the developed PopPK model may provide more benefit
while allowing clinicians to compare various dosing regimens and bridge the plasma
caffeine levels with response at different PCAs and different body weights. Therefore,
dose selecting for alternative targets would be more confirmatory than explorative.
A large variability was estimated for volume of distribution of caffeine from the
final PopPK model. Since most concentration measurements were collected at trough
level of each dosing interval and also at least 40 hours after the loading dose, information
regarding the estimation of volume of distribution is thus limited. As a result, the
optimization of the loading dose was not evaluated in this simulation analysis.
Conclusion
In conclusion, a PopPK model of caffeine was developed for premature infants:
body weight, PCA and information of gestational age were identified as important
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predictors of variability of caffeine pharmacokinetics. Furthermore, we investigated the
application of this PK knowledge to further facilitate the development of optimal dosing
regimens through trial simulation. Various dosing regimens with a dosing interval of 12
or 24 hours were evaluated to reach the predetermined therapeutic target with a trough
level of 8-20 mg/L and a peak level ≤ 40 mg/L at steady state. A dosing interval of 24
hours was shown to be successful with respect to the proposed target concentrations in all
simulated groups. While the modeling and simulation approach is not intended to replace
the TDM, it may provide valuable reference and information when dose adjustment
becomes clinically urgent, especially for those patients with various maturational levels at
the initiation of therapy. The successful use of modeling and simulation approaches in
neonatal and infancy studies may reduce the number of invasive blood drawings required
by therapeutic drug monitoring. Moreover, the posterior predictive check showed
successful dose adjustment within an individual over time. A rational dosing regimen
could be determined more rapidly based on the PopPK characteristics of caffeine rather
than by empirical dosing.
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CHAPTER 5.

SUMMARY

Currently, “off-label” use of drugs in pediatric populations remains an
acknowledged problem across almost all categories of therapeutics throughout the world
[2-9]. It has been reported that up to 62% of pediatric outpatient visits involve off-label or
unlicensed medications [3]. Another report indicated that 70% of the medications in
pediatric intensive care and 90% of the medications in neonatal intensive care were given
in an off-label manner [10]. Off-label prescribing is more common in younger pediatric
populations compared to the older children, especially in premature neonates–the primary
group receiving intensive care [3, 4], and dosing regimens for most drugs used in
neonates are usually empirical. Limited clinical data is considered the major reason for
the “off-label” use of drugs in pediatric populations, due to the complexity of pediatric
studies as well as scientific, logistical and ethical concerns. Major pharmacokinetic
challenges to assuring proper pharmacotherapy in premature neonates and infants are:
limited volume and frequency of blood sample collections, rapid growth and continuous
developmental changes and empirical dosing due to the lack of pharmacokinetic
information. My dissertation research focused on several approaches to overcome these
unique challenges in premature neonates and infants. One of them was to develop an
accurate and sensitive LC-MS/MS assay, which can simultaneously quantitate multiple
drugs frequently used in pediatric pharmacotherapy using a small volume of plasma.
Additionally, PopPK modeling and simulation for sample size estimation and appropriate
study design and dosing regimen were investigated to improve drug development and
pharmacotherapy in pediatric populations.
LC-MS/MS is a standard bioanalytical methodology for drug research due to its
robustness and high sensitivity, which allows for reliable quantification even within the
confines of small sample volumes in pediatric studies [104]. The first objective of my
research was to develop an LC-MS/MS assay for the simultaneous determination of
acetaminophen, caffeine, phenytoin, ranitidine and theophylline using small volume
human plasma specimens for pharmacokinetic evaluation. These five drugs were selected
as they are all currently widely used in the pharmacotherapy of premature and term
neonates [98-103], with only limited pharmacokinetic information available. Due to the
limitations in sample volume, developing an assay that can simultaneously determine
multiple drugs allows for gaining maximal information from pharmacokinetic studies
while minimizing the burden on pediatric patients. An accurate, sensitive, and reliable
LC-MS/MS method was developed and validated using small volume of 50 µL human
plasma to quantitate the selected five drugs simultaneously with mean accuracy ranging
from 87.5% to 115.0%, and intra-day and inter-day precision ranging from 2.8% to
11.8% and from 4.5% to 13.5%, respectively. This assay quantifies a range of 12.2 to
25,000 ng/mL for acetaminophen, phenytoin and ranitidine, a range of 24.4 to 25,000
ng/mL for theophylline, and a range of 48.8 to 25,000 ng/mL for caffeine. These ranges
cover each drug’s therapeutically used concentrations in the neonatal age group. A
sample dilution procedure was also evaluated, and the results indicated that the assay’s
intra-batch accuracy and precision were not affected by the 1-to-2 dilution. The effects of
hemolysis, lipemia and hyperbilirubinemia were subsequently evaluated, and no
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interference in the analysis was noted when these factors existed separately or combined.
Additionally, no significant matrix effect was observed for the developed bioanalytical
assay.
Based on the fact that clinical research in the neonatal population can only be
performed within the context of therapeutically necessary interventions, an opportunistic
sampling approach was proposed for PK studies—that is utilizing the leftover of blood
samples taken for routine clinical care in PK studies. This design is thought to be ethical
since no extra invasive blood draw will be imposed on the patients. Successful
application of population-based M&S can be used to determine the appropriate number of
subjects needed in pediatric studies, thus resulting in fewer patients exposed to the
investigational drugs with an adequately powered study. The effect of sample size on the
robustness of population pharmacokinetic parameter estimates and covariate detection in
the observational study design in premature neonates was evaluated using a full modelbased simulation approach with theophylline as the model drug. Simulated datasets for
each sample size (9-200 subjects per study) with a mixed and unbalanced sampling
design were first generated with the incorporation of changes in birth weight, body
weight and PNA. The median PopPK parameters for theophylline estimated from the
simulated datasets were generally in close agreement with those of the originating model
across all tested sample sizes; while the accuracy, precision and power of parameter
estimation benefit from increases in the number of study subjects. The power of the study
was deeply influenced by the sample size, parameter of interest and the selected precision
level. Furthermore, the power to detect the potential covariate effect was investigated at
three significance levels. It was found if the desired bias in parameter estimations in
terms of %MPE was ≤ 15%, and ≤ 25% and ≤ 50% were accepted as being precise for
fixed effect and variance parameter, respectively, a sample size of 40 subjects would be
sufficient. At a sample size of 40 subjects, the power to detect the covariate effect was
greater than 80% at a significance level of P = 0.01. Overall, this proposed approach can
also be applied to evaluate the impact of other design factors which may influence the
required number of subjects in PK studies in premature infants, such as different
sampling design (sparse or dense sampling), allocation of sampling times, estimation
methods, and magnitude of variability. It may also prove valuable in studying other drugs
of interest if appropriate prior knowledge is available.
There is currently limited PK data on caffeine in premature neonates. We
developed a PopPK model of caffeine in premature neonates and identified potential
sources of variability of PK behavior for caffeine. We subsequently investigated the
application of this PK knowledge to further facilitate the development of optimal dosing
regimens through simulation, particularly to correlate steady state concentrations with
different dosing regimens in various age/body size groups. In the present study, a onecompartment model was chosen to describe the pharmacokinetic characteristics of
caffeine in premature infants, covering a gestational range of 23 to 31 weeks with an age
of up to 116 days. Body weight, PCA and a low gestational age < 25 weeks were found
to be important predictors explaining the between-subject variability of caffeine
pharmacokinetics in premature infants receiving caffeine treatment. Particularly, the BSV
of CL decreased by 68% (from 28% to 8.9%) with the addition of body weight, PCA and
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a low GA factor on CL. The typical patient in the studied premature neonate population
(WT of 1.5 kg, PCA of 32 weeks and with a GA > 25 weeks) was estimated to have a CL
of 0.0164 L/hr and a V of 0.94 L. Finally, we evaluated twelve dose levels from 2-14
mg/kg/day with dosing intervals of 12 or 24 hours in premature infants using trial
simulation. Based on the literature, the therapeutic target was determined to be a trough
level of 8-20 mg/L and a peak level ≤ 40 mg/L at steady state. A dosing interval of 24
hours was shown to be successful for the proposed target concentrations in all simulated
groups. With the proposed dosing regimens, the predetermined target was well attained
and the simulated median trough plasma concentrations were between 8 and 20 mg/L
throughout the treatment period. The dose-optimization simulations based on the
developed PopPK model may provide improved therapeutic benefit while allowing
clinicians to compare various dosing regimens and bridge the plasma caffeine levels with
response at different PCAs and different body weights.
In summary, the general theme of my dissertation research was to investigate
different approaches to overcome the unique pharmacokinetic challenges in clinical
studies with premature neonates and infants. A rapid, accurate, sensitive, and reliable
LC-MS/MS method to quantify five drugs frequently used in the pharmacotherapy of
premature infants simultaneously was developed using a small volume of plasma. This
new bioanalytical assay could facilitate an efficient use of limited blood samples in
premature infants in the future. In addition, an approach was developed using population
pharmacokinetic simulations to determine sample size for PopPK studies in premature
neonates with the consideration of changes in birth weight, body weight and PNA. Lastly,
a PopPK model was developed for caffeine in premature infants with the statistically
significant relationships of clearance with weight, clearance with PCA, clearance with
low GA factor, volume of distribution with weight and volume of distribution with low
GA factor. Proper dosing regimens can be determined rapidly to reach the therapeutic
target concentrations based on the PopPK characteristics of caffeine. Together with the
LC-MS/MS bioanalytical assay, population-based modeling and simulation are highly
useful in supporting clinical pharmacokinetic studies in premature neonates and infants.
With the legislative incentives and requirements, population-based modeling and
simulation approaches as well as sensitive analytical assays allowing for pharmacokinetic
sample quantification from very small volume blood samples, it is hoped that further
information on the influence of developmental changes on pediatric pharmacokinetics
will be gathered to improve pediatric drug labeling so that rationale and scientifically
based dosing strategies can be developed for a safe and effective pharmacotherapy in
pediatric patients.
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Figure A-1. Visual predictive check for the final caffeine population
pharmacokinetic model
The red solid line and grey dotted lines indicate the median and 80% confidence interval
of predicted concentrations determined from 500 Monte Carlo simulations with the Final
Model. Open circles indicate observed caffeine concentrations in the model building
dataset.
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Figure A-2. Visual predictive check for the final caffeine population
pharmacokinetic model
The red solid line and grey dotted lines indicate the median and 70% confidence interval
of predicted concentrations determined from 500 Monte Carlo simulations with the Final
Model. Open circles indicate observed caffeine concentrations in the model building
dataset.
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Figure A-3. Visual predictive check for the final caffeine population
pharmacokinetic model
The red solid line and grey dotted lines indicate the median and 60% confidence interval
of predicted concentrations determined from 500 Monte Carlo simulations with the Final
Model. Open circles indicate observed caffeine concentrations in the model building
dataset.
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Figure A-4. Visual predictive check for the final caffeine population
pharmacokinetic model
The red solid line and grey dotted lines indicate the median and 50% confidence interval
of predicted concentrations determined from 500 Monte Carlo simulations with the Final
Model. Open circles indicate observed caffeine concentrations in the model building
dataset.
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